



ISLAMIC REPUBLIC OF AFGHANISTAN
MINISTRY OF PUBLIC HEALTH
GENERAL DIRECTORATE OF PHARMACEUTICAL AFFAIRS
AVICENNA PHARMACEUTICAL INSTITUTE

National Essential Medicine List of Afghanistan

2014

Preface

With thanks to God for enabling us, we present this revision of the national essential medicines list (EML) and the licensed medicines list (LML) of Afghanistan. These documents are critical to the delivery of quality health services across the country. The policy of the Ministry of Public Health (MoPH) of the Islamic Republic of Afghanistan includes ensuring that the population of Afghanistan has access to safe, effective, and affordable medicines to treat its primary health problems. The EML includes the medicines needed for adequately addressing the priority health problems defined in the MoPH's health strategy. The LML includes the medicines listed in the EML and additional medicines for conditions not included as priorities in the present strategy and medicines used in private sector.

The MoPH developed and published the national EML of Afghanistan for the first time in 1995; the last revision and publication occurred in 2007. The EML and LML should be regularly revised in response to the rapid expansion of basic health services in Afghanistan since 2003, the changing of internationally and nationally recommended treatment protocols for some diseases, the presence of new and emergent diseases, and the withdrawal of medicines for which safer alternatives have become available from treatment guidelines.

To revise the EML and LML, the MoPH authorized the National Medicine Selection Committee (NMSC) to develop a detailed procedure for inclusion or exclusion of medicines from the 2007 lists. The database for tracking updates and edits was also revised, and some new necessary information was added. These procedures will facilitate the mechanism of including new medicines in the EML or LML using logical and comprehensive methods. This procedure conforms to a specific format, guaranteeing the inclusion of new medicines in a scientific and transparent way.

I would like to express my appreciation to the members of the NMSC who oversaw and managed the complicated process of updating the lists. The MoPH is also grateful to the many Afghan and international organizations and individuals who provided assistance and support in the process. We are especially grateful for the sustained technical and financial assistance of the US Agency for International Development (USAID), through the Strengthening Pharmaceutical Systems (SPS) project in Afghanistan, and to the World Health Organization (WHO) Eastern Mediterranean Regional Office, which facilitated the successful revision, publication, and distribution of the updated EML and LML of Afghanistan.

The MoPH warmly recommends that its partners in the public health sector who contribute to the implementation of the basic package of health services (BPHS) and the essential package of hospital services (EPHS) use the EML as the official reference. Likewise, the MoPH warmly recommends that its partners in the private sector who are involved in the production, importation, or distribution of medicines use the LML as an official reference. The use of these two lists will benefit all those working with pharmaceuticals in Afghanistan and will improve their collaboration with the MoPH as it strives to provide quality health services to the people of Afghanistan.


for
Dr. Suraya "Dalil"
Minister of Public Health Kabul, Afghanistan, July 2014

Contents

List of Contributors and Collaborators	4
National Medicine Selection Committee members	4
Contributing MoPH departments and partner institutions	5
Abbreviations and Acronyms	6
Introduction	8
Short History	8
Objectives of the Update	8
Transparent Review Process of EML	9
Classifications of Medicines	9
Procedures for the Inclusion of New Products	10
Computerization	10
Medicine Listings in the EML	11
Detailed Instructions for Use of the EML	11
Where to Obtain Copies and Updates of the EML	12
Essential Medicines List: Anatomical Therapeutic Chemical Classification	13
Essential Medicines List Alphabetical Index	44
Special Programs List	59
National Family Planning Program List	59
National Postpartum Hemorrhage Program List	59
National HIV/AIDS Program List and National Drug Demand Reduction List	60
National Malaria and Leishmania Control Program List	62
National Tuberculosis Program List	63
National Leprosy Program List	64
National EPI Program List	65
Reference Table for Vitamin and Mineral Supplements	66
Annex A. Procedure for Application for Inclusion of Medicines	68
General	68
Types of Applications	68
Submittal and Screening Process	69
Detailed Description of the Application Form	70
Notes on the Application Process	74
References	77
Medicines Index	78

List of Contributors and Collaborators

The following individuals and organizations contributed to different stages in the revision of the National EML and LML.

National Medicine Selection Committee members

Working group members

Pharmacist. Abdul Hafiz Quraishi, General Director, the General Directorate of Pharmaceutical Affairs (GDPA)

Pharmacist. Abdul Khalil Khakzad, Director of Avicenna Pharmaceutical Institute (API)

Pharmacist. Mohammad Zafar Omari, Chief of Party, SPS

Dr. M. Rafi Rahmani, MD, Professor in the Pharmacology Department, Kabul Medical University, Head of the Committee

Pharmacist Haji M. Naimi, Professor and Lecturer, Faculty of Pharmacy, Kabul University

Dr. Abdul Samad Omar, MD, Professor in Surgery, Dean of Medical Faculty. Kabul Medical University

Dr. M. Amin Asghari, MD, Clinical Professor and Head of the Internal Medicine Ward, Wazir Akbar Khan Hospital (WAKH)

Dr. M. Fayaz Safi, MD, Associate Professor, Afghanistan Physicians Association

Pharmacist. Nematullah Nawrozian, Head of Medicine Information Center, API

Pharmacist. Mohammad Asif Yari, Technical Advisor, SPS

Dr. Ahmad Eklil Hayat, Grant and Contract Management Unit (GCMU)

Dr. Safiullah Nadeeb, MD, National Professional Officer WHO

Pharmacist. Mohammad Dawood Mahsoomi, Lecturer, Ghazanfar Institute of Health Science

Pharmacist. Abdul Zahir Siddiqui, Pharmaceutical Services and Field Coordination Program Manager, SPS

Pharmacist. Fahima Habibi, Medicine Resource General Manager, API

Pharmacist. Mohammad Nazir Haidar zad, GDPA Coordinator

Pharmacist. Shekeba Yusoufzai, Essential Medicine Manager, API

Pharmacist. Marzia Abdullah, Medicine Calcification Manager, API

Pharmacist. Mohammad Naser Isalm, National Formulary Manager, API

Pharmacist. Shakilla Amarkhil, Afghanistan Nationwide Pharmacy Association

Dr. Paul Ickx, SPS

Technical Subcommittee members

Pharmacist Aeysha Noorzai, Ministry of Higher Education

Dr. Sultan Mohammad Naji, Head, Chest Surgery Department, Ibn Sina Hospital

Drs. Palwasha Alizai, gynecology and obstetrics specialist

Dr. Shreen Alam, trainer, specialist in burn care

Dr. Mohammd Aref Ibrahimi, ear, nose and throat specialist

Dr. Monir Ahmad Yosoufi, Assistant Chief, Anesthesia Department, Rabia Balkhi Hospital

Dr. Jawed Shohab, trainer, specialist in hematology

Drs. Anisa Hezat, specialist in stomatology

Dr. Abdul Ghafoor Hatef, orthopedic specialist

Dr. Abdul Khalid Amini, SPS

Dr. Yama Noorzad, orthopedic specialist

Pharmacist Said Mohammad Sajjadi, API

Dr. Mohammad Haroon Rasuli,

Dr. Nabil Pakteen, trainer, specialist in cardiac and respiratory diseases

Dr. Ahmad Walid Yosoufzai, trainer, specialist in hematology
Dr. Abdul Moqadas Frozan, specialist in skin disease
Pharmacist Mohammad Nabi Akhtari, API
Dr. Sakhi Ahmad Amiri, specialist in infectious diseases
Dr. Emal Aziz Jabarkhil, specialist in mental and neurological disorders
Dr. Sayed Najibullah Jawed, specialist in mental disorders
Pharmacist Abdullah Jawad, API
Drs. Roqia Naser, MoPH
Dr. Abdul Wali, Ibni Sina Hospital
Dr. Motwali Yonousi, MoPH
Professor Mohammad Hassan Frotan, Faculty of Pharmacy
Dr. Rasheda Formoly, MoPH
Dr. Hamida Hamid, National Malaria and Leishmania Control Program
Dr. Mohammad Yonous Bargami, National HIV/AIDS Program
Dr. Khaled Raheen, National Program of TB Control
Dr. Sher Zaman, National Program of TB Control
Dr. Ahamad Wali Amini, MoPH Nutrition Department
Pharmacist Emal Safi, Sardar Mohd Dawood Hospital
Pharmacist Faizullah Lutfi, API
Dr. Bashir Ahmad Sarwari, Mental Health Department MoPH
Dr. Sher Ahmad Rahmanzai, Afghanistan Nation Medicines Services Organization
Professor Shafiq Mashal, Faculty of Pharmacy, Kabul University
Dr. Hafizullah Mahmudi, SPS
Dr. Ahamad Shah Pardis, WHO
Dr. Mohammad Seddiq Faizi, MoPH

Contributing MoPH departments and partner institutions

Health Management Information System Department, MoPH
HIV/AIDS and Drug Demand Reduction Department, MoPH
Mental Health Department, MoPH
Family Planning Department, MoPH
Nutrition Department, MoPH
Reproductive Health Department, MoPH
Integrated Management of Childhood Illness (IMCI) Department, MoPH
Malaria and Leishmania Control Program, MoPH
GCMU, MoPH
Policy and Planning Department, MoPH
National Tuberculosis Institute, MoPH
World Health Organization, Eastern Mediterranean Regional Office
Strengthening Pharmaceutical Systems Project funded by USAID

Abbreviations and Acronyms

ADHA	attention deficit hyperactivity disorder
API	Avicenna Pharmaceutical Institute
ATC	Anatomical Therapeutic Chemical
BCC	bacillus Calmette-Guérin (TB vaccine)
BHC	basic health center
BPHS	basic package of health services
CHC	comprehensive health center
DH	district hospital
EML	essential medicines list
EPHS	essential package of hospital services
EPI	Expanded Programme on Immunization [WHO]
g	gram
GCMU	Grant and Contract Management Unit
GDPA	General Directorate of Pharmaceutical Affairs
HIV/AIDS	human immunodeficiency virus/acquired immunodeficiency syndrome
HP	health post
HSC	health subcenter
IMCI	Integrated Management of Childhood Illness [WHO]
inj	injection
INN	international nonproprietary name
IU	international units
L	liter
LML	licensed medicines list
mcg	microgram
mEq	milliequivalent
mg	milligram
MLEM	Model List of Essential Medicines [WHO]
MHT	mobile health team
mmol	millimole
MoPH	Ministry of Public Health
mOsm	milliosmole
MSH	Management Sciences for Health
NDDR	National Drug Demand Reduction
NGO	nongovernmental organization
NLP	National Leprosy Program
NMLP	National Malaria and Leishmania Control Program
NMSC	National Medicine Selection Committee
NTP	National Tuberculosis Program
Or	oral
ORS	oral rehydration salts
Osm	osmole

pce	piece
PH	provincial hospital
PPH	postpartum hemorrhage
REACH	Rural Expansion of Afghanistan's Community-Based Health Care
RH	regional hospital
SPS	Strengthening Pharmaceutical Systems
STG	standard treatment guideline
TB	tuberculosis
TFU	therapeutic feeding unit
TSC	technical selection committee
USAID	United States Agency for International Development
USAN	United States Adopted Name
vit	vitamin
WG	working group
WHO	World Health Organization

Introduction

Short History

In 1995 the Ministry of Public Health (MoPH) first published a national essential drugs list (now called the Essential Medicines List [EML]) with the collaboration of the World Health Organization (WHO). In 2003 the EML, which contained 255 items, was republished in collaboration with the USAID-funded Rural Expansion of Afghanistan's Community-Based Health Care (REACH) project and WHO. In 2005, a Licensed Medicine List (LML) for Afghanistan, was published with the financial and technical aid of REACH and WHO. Both lists were revised in 2007 in collaboration with the USAID-funded Tech-Serve Project and WHO. The EML contains all the medicines recommended for use in the Basic Package of Health Services (BPHS), Essential Package of Hospital Services (EPHS), and the MoPH's national programs.

Given the quick development and expansion of the health service delivery system in Afghanistan since 2003, including the development of new treatment protocols and updated WHO recommendations for several diseases as well as withdrawal of some medicines from treatment protocols due to severe adverse drug reactions or the emergence of safer substitutes, the need for updating the EML became urgent. The MoPH constituted a National Medicine Selection Committee (NMSC) in 2012, with a core working group consisting of clinical and pharmaceutical experts from the MoPH, major hospitals, teaching institutes, international agencies, nongovernmental organizations (NGOs), and the private sector. The working group met regularly, delegating the in-depth revision of certain parts of the EML and LML to different subcommittees, drawing in the contribution of a still larger group of experts from the different MoPH task forces, training institutes, NGOs, and international organizations. On October 29, 2013, a draft was presented at a one-day workshop, attended by 112 participants including the Deputy Minister of MoPH, provincial health directorates, pharmacy and medical specialists, provincial pharmacy officers, and representatives of NGOs and private sectors working in health sector. The draft was scrutinized and finalized through intensive group work.

Objectives of the Update

The main objectives of the review process were to—

- Ensure consistency between the BPHS, EPHS, EML, and LML documents based on a rational selection of essential medicines
- Elaborate clear terms of reference for the NMSC, not only for this exercise, but also for revisions in the future
- Adapt the EML to the medicines recommended in the national standard treatment guideline (STG) for the primary level at BPHS level
- Define a detailed and transparent review process that can be used for future revisions
- Define detailed and transparent procedures to control possible exceptions to the EML with administrative and budgetary methods. Similar procedures should apply to requests for deletion of a product that is on the EML or addition of a new entry

Transparent Review Process of EML

Under the guidance and supervision of the General Directorate of Pharmaceutical Affairs (GDPA), the NMSC adhered to the following transparent review process in all stages of the revision to allow future reference to the decisions made.

- Both a clear definition of what documents need to be produced (the EML and LML) and clear procedures for inclusion of new medicines in the lists were provided.
- Working principles were agreed upon, including the management of the review task force and the inclusive consultation of interested parties and stakeholders, without creating a slow and cumbersome process. Realistic deadlines for different stages in the review process were set.
- A list of the reference works that should guide the review process was compiled and included the following:
 - The existing EML
 - The WHO Model List of Essential Medicines (MLEM)—used as the primary guide on efficacy, safety, and quality
 - The Afghan BPHS and EPHS documents
 - Recently updated treatment recommendations from MoPH departments and programs
 - Product lists of recognized international suppliers—a good guide to evaluate availability and cost
 - The *British National Formulary*, *PubMed* and *Martindale*—when other references failed to provide enough information
- Specific selection criteria for inclusion in the EML were defined, including the following:
 - Medicines listed on the WHO MLEM may be included to ensure efficacy, safety, and quality.
 - Medicines listed in the BPHS and EPHS should be included.
 - Medicines recommended in the STG should be included.
 - Included medicines should be available in Afghanistan to ensure access.
 - Included medicines should be available from recognized international suppliers to ensure access and affordable cost.
 - Medicines already donated by international donors should be included to ensure access and affordable cost for certain essential medicines.

Classifications of Medicines

The medicines in the EML are grouped according to the Anatomical Therapeutic Chemical (ATC) classification, promoted by the WHO Collaborating Centre for Drug Statistics Methodology. The medicines are sorted into 14 main groups (first level), with one pharmacological or therapeutic subgroup (second level). The third and fourth levels are the chemical, pharmacological, and therapeutic subgroups, and the fifth level is the chemical substance. The second, third, and fourth levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. For example, ampicillin is classified as follows:

J	Anti-infective for systemic use (main group)
J01	Antibacterial for systemic use (therapeutic subgroup)
J01C	Beta-lactam antibacterial, penicillins (chemical subgroup)
J01CA	Penicillins with extended spectrum (chemical subgroup)
J01CA01	Ampicillin (chemical substance)

Each chemical substance in the EML has its seven-digit ATC code. The same chemical substance can have more than one ATC code, if it is used for different therapeutic purposes. The same substance listed under different administration forms or presentations will have the same ATC code, if the different forms are used for the same therapeutic purpose. The ATC code is not a unique identifier for each individual medicine included in the EML.

If it exists, the international nonproprietary name (INN) is used for the chemical substance. If the INN is not available, either the United States Adopted Name (USAN) or the British Approved Name or other standard name is chosen.

The ATC classification was chosen for the following reasons:

- It contains defined daily doses for many of the products listed.
- It will facilitate studies on consumption of medicines in Afghanistan.
- It will allow a comparison of studies of Afghanistan's pharmaceutical system with studies from other countries.
- It has an equivalent classification system for herbal medicines and veterinary products.
- It is flexible enough to allow temporary classification of a group of products until a specific code is found.

The ATC classification is updated regularly by WHO. The MoPH decided to use the January 2012 version and has adapted the system for use in Afghanistan. The adapted ATC is available from the MoPH on request. The MoPH will not update the ATC classification used in Afghanistan annually, but rather it will most likely do an update every five years.

Procedures for the Inclusion of New Products

The committee drafted detailed instructions for updating and including new products in the EML. The request form and detailed user guides are included in annex A.

Computerization

The GDPA will track future updates and changes in the EML using a database. Presently the database contains all the generic names of the medicines contained in the EML and LML, including recent deletions. For each medicine, the following information is tracked:

- Classification code based on the WHO ATC classification (January 2012 version)
- INN, strength, and presentation—matching, to the extent possible, the name used in the WHO ATC classification
- Alternate generic name under which the medicine is known in Afghanistan
- Median international indicator price and local price, if available
- Whether the medicine is—
 - Included in the EML or LML of Afghanistan
 - Used in the BPHS, the EPHS, or both at this presentation and strength
 - On the controlled substances list of Afghanistan
 - Available without prescription
 - Included in a special program of the MoPH (which may entail restrictions on importation and use)
 - Included in the WHO MLEM (2013 version)

Tracking the medicines using a database allows for the easy production of customized listings for different purposes and also for the storing of historical data on products that are no longer used. This database module has become the core of a more extended database used by the MoPH to track all registered medicines in Afghanistan.

Medicine Listings in the EML

The EML contains an ATC listing of medicines recommended for use in the public sector. Chemical substances are listed under their INN and preparation details, indicating whether and at what level they are recommended for use in the BPHS, the EPHS, or both. If a substance is used for different therapeutic purposes, that substance will be listed under each corresponding group, with a different ATC code. Items are listed in sections up to the third level only. More detailed classification was deemed needlessly cumbersome.

The EML also lists the items included in special lists separately, for use by specific programs of the MoPH. These items are part of the EML, but some are restricted for use by the specific programs of the MoPH as indicated in the special programs lists.

Detailed Instructions for Use of the EML

- The EML contains all items allowable for use in the public sector. The MoPH recommends limiting medicine donations to items and strengths listed in the EML. It contains all medicines recommended for use in the BPHS and EPHS.
- Several medicines are listed for use only in special programs (e.g., opium tincture for the substance abuse program, antiretroviral medicines for the HIV program, misoprostol for the postpartum hemorrhage program). Please refer to the instructions for appropriate use under each program.
- The following presentation forms are interchangeable, meaning that if one is mentioned, the others are allowable as well:
 - Tablets and capsules for oral administration are interchangeable, but sustained-release tablets or capsules are *not* interchangeable with normal tablets or capsules.
 - Creams, ointments, and gels for topical administration are interchangeable.
 - Solutions, syrups, suspensions, and powder for oral administration are interchangeable, but these forms are *not* interchangeable with oral tablets or capsules.
 - Solutions and powders for injectable solution are interchangeable, but aqueous and oily solutions are *not* interchangeable. Normal injections and retard, sustained-release, or long-acting injections are *not* interchangeable.

Example: Amoxicillin 250 mg capsule is listed; amoxicillin 250 mg tablet is accepted as well. Bacitracin ointment is listed; bacitracin cream is accepted as well.

Note: If an oral form is listed, this inclusion does *not* mean that a topical or injectable form is accepted.

- If the volume of a bottle or the weight of a container or tube is mentioned, they will often correspond to a full treatment of the most common patient population using that medicine. The explicitly mentioned volume and weight are minimum limits (i.e., smaller containers will *not* be accepted, but larger containers are acceptable).

Example: Co-trimoxazole oral ingestion suspension 50 ml is listed; co-trimoxazole 40 ml is *not* acceptable; co-trimoxazole 60 ml or 100 ml are acceptable.

- Vitamins and minerals are included in a two different sections:
 - Individual vitamins and minerals are listed in the main list, with exact specifications. Most often these preparations are used for therapeutic purposes.
 - Multivitamins with or without minerals are allowable, as long as the concentration of each active substance per unit dose (e.g., tablet, ml, 5 ml) falls within the limits for supplement

daily intake listed in the “Reference Table for Vitamins and Minerals Supplements” section (table 3). Everything on this table is not necessarily included in the present version of EML or LML. Most often these preparations are used as dietary supplements.

- Oral rehydration salts (ORS) are listed in two forms: 20.5 g/L and 27.9 g/L. The 20.5 g/L solution is recommended by WHO and likewise by the MoPH. All BPHS and EPHS implementers should use the solution given in table 1.

Table 1. Composition of ORS 20.5 g/L

Powder for Dilution in 1 L	
Glucose	75 mEq
Sodium	75 mEq or mmol/L
Chloride	65 mEq or mmol/L
Potassium	20 mEq or mmol/L
Citrate	10 mmol/L
Osmolarity	245 mOsm/L
Glucose	13.5 g/L
Sodium chloride	2.6 g/L
Potassium chloride	1.5 g/L
Trisodium citrate dihydrate ^a	2.9 g/L

^a Trisodium citrate dihydrate may be replaced by sodium hydrogen carbonate (sodium bicarbonate) 2.5 g/L. Because this latter formulation is quite unstable under tropical conditions, however, it is recommended only when it is manufactured for immediate use.

ORS ReSoMal[®] is used only for the management of dehydration in severely malnourished children. Its use is, therefore, dedicated only for therapeutic feeding units (see table 2).

Table 2. Composition of ReSoMal per Liter

Glucose	125 mmol/L
Sodium	45 mmol/L
Potassium	40 mmol/L
Chloride	70 mmol/L
Magnesium	3 mmol/L
Zinc	0.3 mmol/L
Copper	0.045 mmol/L
Citrate	7 mmol/L
Osmolarity	300 mmol/L

- All plasma fractions should comply with the *WHO Requirements for the Collection, Processing and Quality Control of Blood Components and Plasma Derivatives* (revised 1992) (WHO Technical Report Series, no. 840, 1994, annex 2).

Where to Obtain Copies and Updates of the EML

- Printed copies of this version can be obtained from the MoPH, GDPA, API, Essential Medicines Department in Kabul.
- Updated versions will also be available on the websites of the MoPH (www.moph.gov.af) and GDPA (www.gdpa.gov.af).
- For further information please contact at this number: 020-2104659

Essential Medicines List

Anatomical Therapeutic Chemical Classification

Category and Substance	BPHS	EPHS	Special Program
A—ALIMENTARY TRACT AND METABOLISM			
A02—MEDICINES FOR ACID-RELATED DISORDERS			
A02A—Antacids			
Aluminium hydroxide 120 mg + magnesium trisilicate 250 mg per tablet, oral ingestion tablet [A02AD01or]	HP, BHC, CHC, DH	DH, PH, RH	
Aluminium hydroxide 200 mg + magnesium hydroxide 200 mg per tablet, oral ingestion tablet [A02AD01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Aluminium hydroxide 225 mg + magnesium hydroxide 200 mg/5 ml, in 200 ml bottle, oral ingestion suspension [A02AD01or]	HSC, BHC, MHT, CHC, DH		
Aluminium hydroxide 500 mg per tablet, oral chewable tablet [A02AB01or]	HSC, BHC, MHT, CHC, DH		
A02B—Medicines for Peptic Ulcer and Gastroesophageal Reflux Disease (GERD)			
Omeprazole 20 mg per capsule, oral ingestion capsule [A02BC01or]		PH, RH	
Omeprazole 40 mg per capsule, oral ingestion capsule [A02BC01or]		DH, PH, RH	
Omeprazole 40 mg per vial, injection vial [A02BC01or]		PH, NH,	
Ranitidine 150 mg per tablet, oral ingestion tablet [A02BA02or]	CHC, DH	DH, PH, RH	
Ranitidine 25 mg/ml, in 2 ml ampoule, injection solution [A02BA02inj]		DH, PH, RH	
Ranitidine 300 mg per tablet, oral ingestion tablet [A02BA02or]		PH, RH	
A03—MEDICINES FOR FUNCTIONAL GASTROINTESTINAL DISORDERS			
A03B—Belladonna and Derivatives, Plain			
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [A03BA01inj]	CHC, DH	DH, PH, RH	
Atropine sulfate 1 mg per tablet, oral ingestion tablet [A03BA01or]		PH, RH	
Hyoscine (butylbromide, hydrobromide) 10 mg per tablet, oral ingestion tablet [A03BB01or]		PH, RH	
Hyoscine (butylbromide, hydrobromide) 20 mg/ml, in 1 ml ampoule, injection solution [A03BB01inj]		DH, PH, RH	
A03F—Propulsives			
Metoclopramide 10 mg per tablet, oral ingestion tablet [A03FA01or]	HSC, BHC, CHC, DH	DH, PH, RH	
Metoclopramide 5 mg/ml, in 2 ml ampoule, injection solution [A03FA01inj]	HSC, BHC, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
A06—LAXATIVES			
A06A—Laxatives			
Bisacodyl 5 mg per tablet, oral ingestion tablet [A06AB02or]	DH	DH, PH, RH	
Lactulose 3.33 g/5 ml, in 150 ml bottle, oral ingestion syrup [A06AD11or]	CHC, DH	DH, PH, RH	
A07—ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY, AND ANTI-INFECTIVE MEDICINES			
A07A—Intestinal Anti-Infectives			
Nystatin 100,000 IU/ml, in 15 ml oral topical drop [A07AA02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Nystatin 100,000 IU per tablet, oral ingestion tablet [A07AA02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Nystatin 500,000 IU per tablet, oral ingestion tablet [A07AA02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
A07B—Intestinal Adsorbents			
Activated charcoal 1 g per tablet, oral ingestion tablet [A07BA01or]		DH, PH, RH	
Activated charcoal 500 mg per tablet, oral ingestion tablet [A07BA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
A07C—Electrolytes with Carbohydrates			
Oral rehydration salts (ORS), 20.5 g/L, in 1 L sachet, oral ingestion powder [A07CA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Oral rehydration salts (ORS), 27.9 g/L, in 1 L sachet, oral ingestion powder [A07CA01or]	HP, BHC, CHC, DH	DH, PH, RH	
Oral rehydration salts (ORS) ReSoMal in 1 L sachet, oral ingestion powder [A07CA01or]		PH, RH	TFU
A10—MEDICINES USED IN DIABETES			
A10A—Insulins and Analogues			
Insulin isophane (NPH) intermediate 100 IU/ml, in 10 ml vial, injection vial [A10AC03inj]		PH, RH	
Insulin isophane (NPH) intermediate 40 IU/ml, in 10 ml vial, injection vial [A10AC03inj]		RH	
Insulin soluble fast 100 IU/ml, in 10 ml vial, injection vial [A10AB01inj]		PH, RH	
Insulin soluble fast 40 IU/ml, in 10 ml vial, injection vial [A10AB01inj]		RH	
A10B—Blood Glucose Lowering Medicines, Excluding Insulins			
Glibenclamide 5 mg per tablet, oral ingestion tablet [A10BB01or]		PH, RH	
Metformin 500 mg per tablet, oral ingestion tablet [A10BA02or]		PH, RH	

Category and Substance	BPHS	EPHS	Special Program
A11—VITAMINS			
A11A—Multivitamins, Combinations			
Multivitamins and other minerals, including combinations [A11AA03]	HP, BHC, CHC, DH	DH, PH, RH	
Multiple micronutrient formulation per sachet (1 g sachet), oral ingestion powder [A11AA03or] (iron 10 mg EFF + vit A 400 mcg RE + zinc 4.1 mg Zn G + vit C 30 mg AA + folic acid 90 mcg + vit D3 5.0 mcg + vit E 5.0 mg TE + vit B1 0.5 mg + vit B2 0.5 mg + vit B6 0.5 mg + vit B12 0.9 mcg + niacin 6.0 mg + copper 0.56 mg CuS + iodine 90 mcg KI + selenium 17 mcg NaS per sachet)	HP, HSC, BHC, MHT, CHC, DH	DH	
Multiple micronutrient formulation 500 mg tablet, oral ingestion tablet [A11AA03or] (iron 30 mg EFF + vit A 800 mcg RE + zinc 15 mg Zn G + vit C 70 mg AA + folic acid 400 mcg + vit D3 5.0 mcg + vit E 10 mg TE+ vit B1 1.4 mg + vit B2 1.4 mg + vit B6 1.9 mg + vit B12 2.6 mcg + niacin 18.0 mg + copper 2.0 mg CuS + iodine 150 mcg KI + selenium 65 mcg NaS per tablet)	HP, HSC, BHC, MHT, CHC, DH	DH	
Multivitamins and trace elements [A11AA04]	HP, BHC, CHC, DH	DH, PH, RH	
Multivitamins, other combinations [A11AB00]	HP, BHC, CHC, DH	DH, PH, RH	
A11C—Vitamins A and D, Including Combinations of the Two			
Colecalciferol (vit D3) 600,000 IU/ml, injection ampoule [A11CC05inj]	CHC, DH	DH, PH, RH	
Retinol (oily) (vit A) 100,000 IU/ml, oral solution [A11CA01or]		RH	
Retinol (vit A) 100,000 IU per ampoule, injection ampoule [A11CA01inj]		RH	
Retinol (vit A) 100,000 IU per tablet, oral ingestion tablet [A11CA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Retinol (vit A) 200,000 IU per tablet, oral ingestion tablet [A11CA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
A11H—Other Plain Vitamin Preparations			
Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [A11HA11or]		DH, PH, RH	
Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [A11HA11or]	BHC, CHC, DH	DH, PH, RH	
Pyridoxine (vit B6) 25 mg per tablet, oral ingestion tablet [A11HA02or]	DH	DH, PH, RH	
Pyridoxine (vit B6) 40 mg per tablet, oral ingestion tablet [A11HA02or]	DH	DH, PH, RH	
A12—MINERAL SUPPLEMENTS			
A12A—Calcium			
Calcium gluconate 10% in 10 ml ampoule, injection ampoule [A12AA03inj]	HSC, BHC, MHT, CHC, DH	PH, RH	

Category and Substance	BPHS	EPHS	Special Program
A12C—Other Mineral Supplements			
Zinc sulfate 10 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Zinc sulfate 20 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
B—BLOOD AND BLOOD-FORMING ORGANS			
B01—ANTITHROMBOTIC AGENTS			
B01A—Antithrombotic Agents			
Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [B01AC06or]	BHC*, CHC, DH	DH, PH, RH	
Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [B01AC06or]		PH, RH,	
Enoxaparin 100 mg/ml, in 1 ml ampoule, injection solution [B01AB05inj]		DH, PH, RH	
Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]		PH, RH	
Heparin 2,500 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]		PH, RH	
Heparin 5,000 IU/ml, in 1ml ampoule, injection solution [B01AB01inj]		PH, RH	
B02—ANTIHEMORRHAGICS			
B02B—Vitamin K and Other Hemostatics			
Coagulation factor II, VII, IX, X per ampoule, injection solution [B02BD01inj]	DH,	DH, PH, RH,	
Coagulation factor VIII per ampoule, injection solution [B02BD02inj]	DH,	DH, PH, RH,	
Phytomenadione (vit K) 10 mg/ml, in 1 ml ampoule, injection solution [B02BA01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Phytomenadione (vit K) 10 mg per tablet, oral ingestion tablet [B02BA01or]		PH, RH	
B03—ANTIANEMIC PREPARATIONS			
B03A—Iron Preparations			
Ferrous sulfate 125 mg/5 ml, in 120 ml, oral ingestion liquid [B03AA07or]	HSC, BHC, MHT, CHC, DH		
Ferrous sulfate 60 mg per tablet, oral ingestion tablet [B03AA07or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Ferrous sulfate 60 mg + folic acid (vit B9) 0.4 mg per tablet, oral ingestion tablet [B03AD03or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Iron dextran 50 mg/ml, in 2 ml ampoule, injection solution [B03AC06inj]		RH	

Category and Substance	BPHS	EPHS	Special Program
B03B—Vitamin B12 and Folic Acid			
Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [B03BB01or]	HSC, BHC, MHT, CHC, DH	PH, RH	
Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [B03BB01or]	HSC, BHC, MHT, CHC, DH	PH, RH	
Hydroxocobalamine (vit B12) 0.5 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]		PH, RH	
Hydroxocobalamine (Vit B12) 1 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]		PH, RH	
B05—BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS			
B05A—Blood and Related Products			
Dextran 70 6% injection solution [B05AA05inj]		RH	
B05B—I.V. Solutions			
Glucose 4% + sodium chloride 0.18% in 1,000 ml bottle, injection solution [B05BB02inj]	BHC, CHC, DH	DH, PH, RH	
Glucose 4% + sodium chloride 0.18% in 500 ml bottle, injection solution [B05BB02inj]	BHC, CHC, DH	DH, PH, RH	
Glucose 5% + sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB02inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Glucose 5% + sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB02inj]	BHC, CHC, DH	DH, PH, RH	
Glucose 50% injection solution [B05BA03inj]	CHC, DH	DH, PH, RH	
Mannitol 10% in 100 ml bottle, infusion solution [B05BC01inj]		RH	
Mannitol 20% in 100 ml bottle, infusion solution [B05BC01inj]		RH	
Ringer's lactate in 1,000 ml, infusion solution [B05BB02inj]	BHC, CHC, DH	DH, PH, RH	
Ringer's lactate in 500 ml, infusion solution [B05BB02inj]	BHC*, CHC, DH	DH, PH, RH	
Sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB01inj]	HSC, BHC, MHT, CHC, DH,	DH, PH, RH	
Sodium chloride 0.9% in 500ml bottle, injection solution [B05BB01inj]	HSC, BHC, MHT, CHC, DH,	DH, PH, RH	
B05C—Irrigating Solutions			
Glucose 10% in 1,000 ml bottle, injection solution [B05CX01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Glucose 10% in 500 ml bottle, injection solution [B05CX01inj]	BHC, CHC, DH	DH, PH, RH	
Glucose 5% in 1,000 ml bottle, injection solution [B05CX01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Glucose 5% in 500 ml bottle, injection solution [B05CX01inj]	BHC, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
Sodium bicarbonate 1.4% in 20 ml vial, injection vial [B05CB04inj]		RH	
Sodium bicarbonate 8.4% in 10 ml vial, injection vial [B05CB04inj]	MHT, CHC, DH	DH, RH	
B05D—Peritoneal Dialytics			
Peritoneal dialytics, isotonic solutions in 1,000 ml per bag, parenteral solution [B05DA00]			
B05X—I.V. Solution Additives			
Potassium chloride 11.2% in 20 ml ampoule, injection solution [B05XA01inj]	HSC*, BHC*, MHT, CHC, DH	RH	
Potassium chloride 15% in 20 ml ampoule, injection solution [B05XA01inj]	CHC, DH	RH	
Potassium chloride 7.5% in 20 ml ampoule, injection solution [B05XA01inj]	CHC, DH	RH	
C—CARDIOVASCULAR SYSTEM			
C01—CARDIAC THERAPY			
C01A—Cardiac Glycosides			
Digoxin 0.25 mg/ml, in 2 ml ampoule, injection solution [C01AA05inj]		PH, RH	
Digoxin 0.25 mg per tablet, oral ingestion tablet [C01AA05or]		DH, PH, RH	
C01B—Antiarrhythmics, Classes I and III			
Lidocaine 20 mg/ml, in 5 ml ampoule, injection solution [C01BB01inj]		RH	
Procainamide 100 mg/ml, in 10 ml ampoule, injection solution [C01BA02inj]		RH	
Procainamide 250 mg per tablet, oral ingestion tablet [C01BA02or]		RH	
C01C—Cardiac Stimulants Excluding Cardiac Glycosides			
Dopamine 40 mg/ml, in 5 ml vial, injection solution [C01CA04inj]		RH	
Epinephrine (adrenaline) 0.1% in 1 ml ampoule, injection solution [C01CA24inj]	HSC*, BHC*, MHT*, CHC, DH	DH, PH, RH	
C01D—Vasodilators Used in Cardiac Diseases			
Glyceryl trinitrate (nitroglycerine) 0.5 mg per tablet, sublingual-oral tablet [C01DA02or]		RH	
Isosorbide dinitrate 10 mg per tablet, sublingual-oral tablet [C01DA08or]	DH	DH, PH, RH	
Isosorbide dinitrate 20 mg per tablet, sublingual-oral tablet [C01DA08or]	DH, PH, RH		
Isosorbide dinitrate 5 mg per tablet, sublingual-oral tablet [C01DA08or]	DH	DH, PH, RH	
C02—ANTIHYPERTENSIVES			
C02A—Antiadrenergic Agents, Centrally Acting			
Methyldopa 250 mg per tablet, oral ingestion tablet [C02AB01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
C02D—Arteriolar Smooth Muscle, Agents Acting On			
Hydralazine 20 mg/ml, in 2 ml, injection solution [C02DB01inj]	DH	DH, PH, RH	
Hydralazine 25 mg per tablet, oral ingestion tablet [C02DB02or]		RH	
Hydralazine 50 mg per tablet, oral ingestion tablet [C02DB02or]		RH	
C03—DIURETICS			
C03A—Low-Ceiling Diuretics, Thiazides			
Hydrochlorothiazide 25 mg per tablet, oral ingestion tablet [C03AA03or]		PH, RH	
Hydrochlorothiazide 50 mg per tablet, oral ingestion tablet [C03AA03or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
C03C—High-Ceiling Diuretics			
Furosemide 10 mg/ml, in 2 ml ampoule, injection solution [C03CA01inj]	DH	DH, PH, RH	
Furosemide 20 mg per tablet, oral ingestion tablet [C03CA01or]	CHC, DH	DH	
Furosemide 40 mg per tablet, oral ingestion tablet [C03CA01or]	, , PH, RH		
C03D—Potassium-Sparing Agents			
Spironolactone 25 mg per tablet, oral ingestion tablet [C03DA01or]		RH	
Spironolactone 50mg per tablet, oral ingestion tablet [C03DA01or]		RH	
C07—BETA-BLOCKING AGENTS			
C07A—Beta-Blocking Agents			
Atenolol 100 mg per tablet, oral ingestion tablet [C07AB03or]	MHT, CHC, DH	DH, PH, RH	
Atenolol 25 mg per tablet, oral ingestion tablet [C07AB03or]	BHC*, CHC, DH	DH, RH	
Atenolol 50 mg per tablet, oral ingestion tablet [C07AB03or]	MHT, CHC, DH	DH, RH	
Metoprolol 1 mg/ml, in 5 ml ampoule, injection solution [C07AB02inj]	DH	DH, PH, RH	
Metoprolol 50 mg per tablet, oral ingestion tablet [C07AB02or]		DH, PH, RH	
Propranolol 10 mg per tablet, oral ingestion tablet [C07AA05or]	PH, RH		
Propranolol 20 mg per tablet, oral ingestion capsule or tablet [C07AA05or]	DH	DH, PH, RH,	
Propranolol 40 mg per tablet, oral ingestion tablet [C07AA05or]		PH, RH	
C08—CALCIUM CHANNEL BLOCKERS			
C08C—Selective Calcium Channel Blockers with Mainly Vascular Effects			
Amlodipine 5 mg per tablet, oral ingestion tablet [C08CA01or]	BHC*, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
Nifedipine slow-release 10 mg per tablet, oral ingestion tablet [C08CA05or]	BHC*, MHT*, CHC, DH	DH, PH, RH	
Nifedipine slow-release 20 mg per tablet, oral ingestion tablet [C08CA05or]	BHC*, CHC, DH	DH, PH, RH	
C08D—Selective Calcium Channel Blockers with Direct Cardiac Effects			
Verapamil 2.5 mg/ml, in 2 ml ampoule, injection solution [C08DA01inj]		RH	
Verapamil 40 mg per tablet, oral ingestion tablet [C08DA01or]		RH	
Verapamil 80 mg per tablet, oral ingestion tablet [C08DA01or]		RH	
C09—AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM			
C09A—Ace Inhibitors, Plain			
Captopril 25 mg per tablet, oral ingestion tablet [C09AA01or]		RH	
Enalapril 10 mg per tablet, oral ingestion tablet [C09AA02or]		RH	
C10—LIPID-MODIFYING AGENTS			
C10A—Lipid-Modifying Agents, Plain			
Atorvastatin 20 mg per tablet, oral ingestion tablet [C10AA05or]		PH, RH	
Colestyramine (cholestyramine) 4 g per sachet, oral ingestion powder [C10AC01or]		PH, RH	
Fenofibrate 200 mg per capsule, oral ingestion capsule [C10AB05or]		PH, RH	
D—DERMATOLOGICALS			
D01—ANTIFUNGALS FOR DERMATOLOGICAL USE			
D01A—Antifungals for Topical Use			
Ketoconazole 2% in 15 g tube, topical cream [D01AC08]		PH, RH	
Ketoconazole 2% in 60 ml, topical shampoo [D01AC08]		PH, RH	
Methylrosaniline (gentian violet) 0.5% in 10 ml bottle, topical solution [D01AE02]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Methylrosaniline (gentian violet) 1% in 10 ml bottle, topical solution [D01AE02]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Methylrosaniline (gentian violet) 25 g per bottle, topical crystals [D01AE02]	HP, BHC, CHC, DH	DH, PH, RH	
Nystatin 100,000 IU/g, in 25 g tube, topical cream [D01AA01]	BHC, CHC, DH	PH, RH	
Salicylic acid 5%, topical solution [D01AE12]		PH, RH	
Terbinafine 1% in 30 g tube, topical cream [D01AE15]			
Tolnaftate 1% topical cream [D01AE18]		RH	

Category and Substance	BPHS	EPHS	Special Program
D01B—Antifungals for Systemic Use			
Griseofulvin 125 mg per tablet, oral ingestion tablet [D01BA01or]		PH, RH	
Griseofulvin 250 mg per tablet, oral ingestion tablet [D01BA01or]		PH, RH	
Griseofulvin 500 mg per tablet, oral ingestion tablet [D01BA01or]		PH, RH	
Terbinafine 125 mg per tablet, oral ingestion tablet [D01BA02or]		PH, RH	
Terbinafine 250 mg per tablet, oral ingestion tablet [D01BA02or]		PH, RH	
D02—EMOLLIENTS AND PROTECTIVES			
D02A—Emollients and Protectives			
Retinol (vit A) 850 IU + colecalciferol (vit D3) 85 IU/g, in 30 g tube, topical ointment [D02AX00]	DH		
Zinc oxide 10% in 20 g tube, topical ointment [D02AB01]		PH, RH	
Zinc oxide 20% in 20 g tube, topical cream [D02AB01]	DH	DH, PH, RH	
D04—ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANESTHETICS, AND OTHERS			
D04A—Antipruritics, including Antihistamines, Anesthetics, and Others			
Calamine (ZnO + Fe2O3) 8% in 30 g tube, topical cream [D04AX01]		PH, RH,	
Calamine (ZnO + Fe2O3) 8% in 60 ml bottle topical lotion [D04AX01]	BHC, CHC, DH	DH, PH, RH	
Lidocaine 2% in 15 g tube, topical gel [D04AB04]	HSB, BHC, MHT, CHC, DH	DH, PH, RH	
Lidocaine 4% topical gel [D04AB04]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
D05—ANTIPSORIATICS			
D05A—Antipsoriatics for Topical Use			
Coal tar 5% in 100 g bottle, topical lotion [D05AA01]		RH	
D06—ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE			
D06A—Antibiotics for Topical Use			
Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]	DH	DH, PH, RH	
Mupirocin 2% in 10 g tube, topical cream [D06AX09]			
D06B—Chemotherapeutics dor Topical Use			
Metronidazole 0.75% in 15 g tube, topical ointment [D06BX01]		RH	
Silver sulfadiazine 1% in 500 g container, topical cream [D06BA01]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Silver sulfadiazine 1% in 20g tube, topical cream [D06BA01]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
D07—CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS			
D07A—Corticosteroids, Plain			
Hydrocortisone acetate 1% in 15 g tube, topical cream [D07AA02]		RH	
D07C—Corticosteroids, Combinations with Antibiotics			
Betamethasone 0.1% + neomycin 0.5% in 15 g tube, topical cream [D07CC01]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
D08—ANTISEPTICS AND DISINFECTANTS			
D08A—Antiseptics and Disinfectants			
Boric acid + glycerin 5% (glycerin boric) in 10 ml, topical solution [D08AD01]		RH	
Cetrimide 15% + chlorhexidine gluconate 1.5% topical solution [D08AC52]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chlorhexidine digluconate 7.1% topical solution or gel [D08AC02]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chlorhexidine digluconate 5% topical solution [D08AC02]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Hydrogen peroxide 6% topical solution [D08AX01]		PH, RH	
Potassium permanganate 0.01% topical solution [D08AX06]		PH, RH	
Povidone iodine 10% topical solution [D08AG02]		PH, RH	
Sodium hypochlorite (chlorine) 0.5% topical solution [D08AX07]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
D10—ANTI-ACNE PREPARATIONS			
D10A—Anti-Acne Preparations for Topical Use			
Benzoyl peroxide 5% topical cream [D10AE01]		RH	
Benzoyl peroxide 5% topical lotion [D10AE01]		RH	
Sulfur 2% + salicylic acid 1% topical ointment [D10AB02]			
G—GENITOURINARY SYSTEM AND SEX HORMONES			
G01—GYNECOLOGICAL ANTI-INFECTIVES AND ANTISEPTICS			
G01A—ANTI-INFECTIVES AND ANTISEPTICS, EXCLUDING COMBINATIONS			
Furazolidone 100 mg per tablet, oral ingestion tablet [G01AX06or]		RH	
Furazolidone 125 mg/5 ml, in 60 ml, oral syrup [G01AX06or]		RH	
Nystatin 100,000 IU/g, in 15 g tube, vaginal cream [G01AA01vg]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Nystatin 100,000 IU per ovule, vaginal suppository [G01AA01vg]	BHC, CHC, DH	DH, PH, RH	
Nystatin 100,000 IU per tablet, vaginal tablet [G01AA01vg]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
G02—OTHER GYNECOLOGICALS			
G02A—Oxytocics			
Ergometrine maleate 0.2 mg/ml, injection solution [G02AB03inj]	HSC, BHC, CHC, DH	DH, PH, RH	
Ergometrine maleate 0.2 mg per tablet, oral ingestion tablet [G02AB03or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Methylethergometrine maleate 0.2 mg/ml, in 1 ml, injection ampoule [G02AB01inj]	BHC, CHC, DH	DH, PH, RH	
Misoprostol 200 mcg per tablet, oral ingestion tablet [G02AD20or]			PPH
Misoprostol 25 mcg per tablet, vaginal tablet [G02AD06vg]			PPH
G02B—Contraceptives for Topical Use			
Condom with and without nonoxinol 1 pce per piece, topical [G02BX01]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP
Intrauterine device with copper 1 pce per piece, vaginal intrauterine device [G02BA02]	BHC*, CHC, DH	DH, PH, RH	FP
G02C—Other Gynecologicals			
Nifedipine 10 mg per tablet, oral ingestion tablet [G02CA04or]	BHC*, MHT*, CHC, DH	DH, PH, RH	
Nifedipine 20 mg per capsule, oral ingestion capsule [G02CA04or]	CHC, DH	DH, PH, RH	
G03—SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM			
G03A—Hormonal Contraceptives for Systemic Use			
Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet [G03AA05or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP
Ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per tablet, oral ingestion tablet [G03AA07or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet [G03AA06or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP
Ethinylestradiol 0.05 mg + levonorgestrel 0.25 mg per tablet, oral ingestion tablet [G03AA07or]	HP, HSC, BHC, MHT, CHC, DH	DH, RH	
Levonorgestrel 0.03 mg per tablet, oral ingestion tablet [G03AC03or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP
Medroxyprogesterone acetate depot 150 mg/ml, in 1 ml vial, injection solution [G03AC06inj]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP
Norgestrel 0.075 mg per tablet, oral ingestion tablet [G03AC10or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	FP

Category and Substance	BPHS	EPHS	Special Program
G03C—Estrogens			
Ethinylestradiol 0.01 mg per tablet, oral ingestion tablet [G03CA01or]		RH	
Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [G03CA01or]	HP, BHC, CHC, DH	RH	
G03D—Progestogens			
Norethisterone 5 mg per tablet, oral ingestion tablet [G03DC02or]			
G03G—Gonadotropins and Other Ovulation Stimulants			
Clomifene 50 mg per tablet, oral ingestion tablet [G03GB02or]		RH	
H—SYSTEMIC HORMONAL PREPARATIONS, EXCLUDING SEX HORMONES AND INSULINS			
H01—PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES			
H01B—Posterior Pituitary Lobe Hormones			
Oxytocin 10 IU/ml, in 1 ml ampoule, injection solution [H01BB02inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
H02—CORTICOSTEROIDS FOR SYSTEMIC USE			
H02A—Corticosteroids for Systemic Use, Plain			
Hydrocortisone sodium succinate 100 mg per vial, injection vial [H02AB09inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Prednisolone 5 mg per tablet, oral ingestion tablet [H02AB06or]	DH	DH, PH, RH	
H03—THYROID THERAPY			
H03A—Thyroid Preparations			
Levothyroxine 0.05 mg per tablet, oral ingestion tablet [H03AA01or]		RH	
Levothyroxine 0.1 mg per tablet, oral ingestion tablet [H03AA01or]		RH	
H03B—Antithyroid Preparations			
Carbimazole 5 mg per tablet, oral ingestion tablet [H03BB01or]		RH	
H03C—Iodine Therapy			
Iodine 200 mg per capsule, oral ingestion capsule [H03CA20or]	HSC, BHC, MHT, CHC, DH	DH, RH	
Iodine 480 mg/ml, in 0.5 ml ampoule, oral ampoule [H03CA20or]		RH	
Iodine 540 mg/ml, in 0.57 ml bottle, oral solution [H03CA20or]	HSC, BHC, MHT, CHC, DH	DH, RH	
J—ANTI-INFECTIVES FOR SYSTEMIC USE			
J01—ANTIBACTERIALS FOR SYSTEMIC USE			
J01A—Tetracyclines			
Doxycycline 100 mg per capsule, oral ingestion capsule [J01AA02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
J01B—Amphenicols			
Chloramphenicol 125 mg/5 ml, in 100 ml bottle, oral syrup [J01BA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chloramphenicol 1 g per vial, injection powder [J01BA01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chloramphenicol 250 mg per capsule, oral ingestion capsule [J01BA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chloramphenicol 500 mg per vial, injection powder [J01BA01inj]		DH, PH, RH	
J01C—Beta-Lactam Antibacterials, Penicillins			
Amoxicillin 125 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Amoxicillin 125 mg + clavulanic acid 31.25 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CR02or]		RH	
Amoxicillin 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]		PH, RH	
Amoxicillin 250 mg per tablet, oral ingestion tablet [J01CA04or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Amoxicillin 500 mg per tablet, oral ingestion tablet [J01CA04or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Amoxicillin 500 mg + clavulanic acid 125 mg (co-amoxiclav) per tablet, oral ingestion tablet [J01CR02or]		RH	
Ampicillin 1 g per vial, injection powder [J01CA01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Ampicillin 500 mg per vial, injection powder [J01CA01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Cloxacillin 250 mg per capsule, oral ingestion capsule [J01CF02or]		PH, RH	
Cloxacillin 500 mg per capsule, oral ingestion capsule [J01CF02or]	CHC, DH	DH, PH, RH	
Cloxacillin 500 mg per vial, injection powder [J01CF02inj]	DH	DH, PH, RH	
Penicillin benzyl (peni G crystal) 1 MU per vial, injection vial [J01CE01inj]	BHC*, CHC, DH	DH, PH, RH	
Penicillin benzyl (peni G crystal) 5 MU per vial, injection vial [J01CE01inj]	BHC*, CHC, DH	DH, PH, RH	
Penicillin benzyl 0.5 MU + penicillin procaine 1.5 MU per vial, injection vial [J01CE09inj]	BHC*, CHC, DH		
Penicillin benzyl 1 MU + penicillin procaine 3 MU per vial, injection vial [J01CE09inj]	BHC*, CHC, DH		

Category and Substance	BPHS	EPHS	Special Program
Penicillin benzyl 2 MU + penicillin procaine 6 MU per vial, injection vial [J01CE09inj]	BHC*, CHC, DH		
Penicillin benzyl benzathine 1.2 MU per vial, injection vial [J01CE08inj]	HSC*, BHC*, MHT*, CHC, DH	DH, PH, RH	
Penicillin benzyl benzathine 2.4 MU per vial, injection vial [J01CE08inj]	HSC*, BHC*, MHT*, CHC, DH	DH, PH, RH	
Penicillin benzyl procaine 2 MU per vial, injection vial [J01CE09inj]	BHC*, MHT*, CHC, DH	DH, PH, RH	
Penicillin benzyl procaine 4 MU per vial, injection vial [J01CE09inj]	BHC*, MHT*, CHC, DH	DH, PH, RH	
Penicillin V (phenoxymethylpenicillin) 250 mg/5 ml, in 100 ml bottle, oral ingestion suspension [J01CE02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH,	
Penicillin V (phenoxymethylpenicillin) 250 mg per tablet, oral ingestion tablet [J01CE02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Penicillin V (phenoxymethylpenicillin) 500 mg per tablet, oral ingestion tablet [J01CE02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
J01D—Other Beta-Lactam Antibacterials			
Ceftriaxone 1 g per vial, injection powder [J01DD04inj]		PH, RH	
Ceftriaxone 500 mg per vial, injection powder [J01DD04inj]	DH	DH, PH, RH	
J01E—Sulfonamides and Trimethoprim			
Sulfamethoxazole 100 mg + trimethoprim 20 mg (co-trimoxazole) per tablet, oral ingestion tablet [J01EE01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Sulfamethoxazole 200 mg + trimethoprim 40 mg (co-trimoxazole)/5 ml, in 50 ml bottle, oral ingestion suspension [J01EE01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Sulfamethoxazole 400 mg + trimethoprim 80 mg (co-trimoxazole) per tablet, oral ingestion tablet [J01EE01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
J01F—Macrolides, Lincosamides, and Streptogramins			
Azithromycin 250 mg per capsule, oral ingestion capsule [J01FA10or]	DH	DH,PH,RH	
Azithromycin 500 mg per capsule, oral ingestion capsule [J01FA10or]	DH	DH,PH,RH	
Clindamycin 150 mg per capsule, oral ingestion capsule [J01FF01or]	CHC, DH	DH, PH, RH,	
Clindamycin 900 mg + dextrose 5% in 50 ml, parenteral infusion [J01FF01inj]		RH	
Erythromycin (base) 125 mg/5 ml, in 60 ml, oral ingestion suspension [J01FA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Erythromycin (ethylsuccinate) 200 mg per tablet, oral ingestion tablet [J01FA01or]		PH, RH	

Category and Substance	BPHS	EPHS	Special Program
Erythromycin (ethylsuccinate) 400 mg per tablet, oral ingestion tablet [J01FA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Erythromycin stearate 250 mg per tablet, oral ingestion tablet [J01FA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Erythromycin stearate 500 mg per tablet, oral ingestion tablet [J01FA01or]		DH, PH, RH	
J01G—Aminoglycoside Antibacterials			
Amikacin 500 mg/ml, in 2 ml vial, injection vial [J01GB06inj]		DH, PH, RH	
Gentamicin 10 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Gentamicin 20 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]	, , , ,	DH, PH, RH	
Gentamicin 40 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Streptomycin 1 g per vial, injection vial [J01GA01inj]	HSC, BHC, CHC, DH	DH, PH, RH	
J01M—Quinolone Antibacterials			
Ciprofloxacin 250 mg per tablet, oral ingestion tablet [J01MA02or]	CHC, DH	DH, PH, RH	
Ciprofloxacin 2 mg/ml, in 50 ml ampoule, infusion solution [J01MA02inj]		PH, RH	
Ciprofloxacin 500 mg per tablet, oral ingestion tablet [J01MA02or]		PH, RH	
Moxifloxacin 400 mg per tablet, oral ingestion tablet [J01MA14or]	MHT, BHC, CHC, DH	PH, RH,	NTP
Nalidixic acid 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01MB02or]		RH	
Nalidixic acid 250 mg per tablet, oral ingestion tablet [J01MB02or]		RH	
Nalidixic acid 500 mg per tablet, oral ingestion tablet [J01MB02or]		RH	
J01X—Other Antibacterials			
Metronidazole 5 mg/ml, in 100 ml bottle, oral ingestion solution [J01XD01inj]	CHC, DH	PH, RH	
Nitrofurantoin 100 mg per tablet, oral ingestion tablet [J01XE01or]	MHT, CHC, DH	DH, PH, RH	
J02—ANTIMYCOTICS FOR SYSTEMIC USE			
J02A—Antimycotics Ffor Systemic Use			
Ketoconazole 200 mg per tablet, oral ingestion tablet [J02AB02or]		PH, RH	

Category and Substance	BPHS	EPHS	Special Program
J04—ANTIMYCOBACTERIALS			
J04A—Medicines for Treatment of Tuberculosis			
Capreomycin 1 g per vial, injection powder [J04AB30inj]	HP, MHT, BHC, CHC, DH	DH, PH, RH	NTP
Cycloserine 250 mg per capsule, oral ingestion capsule [J04AB01or]	HP, BHC, CHC, DH	DH, PH, RH	NTP
Ethambutol (E) 275 mg + isoniazid (H) 75 mg + pyrazinamide (Z) 400 mg + rifampicin (R) 150 mg (RHZE) per tablet, oral capsule or tablet [J04AM06or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet [J04AK02or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet [J04AK02or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Ethambutol 400 mg + isoniazid 150 mg (EH) per tablet, oral ingestion tablet [J04AK02or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet [J04AM03or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Ethionamide 250 mg per tablet, oral ingestion tablet [J04AD03or]	HP, BHC, CHC, DH	DH, PH, RH,	NTP
Isoniazid (INH) 100 mg per tablet, oral ingestion tablet [J04AC01or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Isoniazid (INH) 300 mg per tablet, oral ingestion tablet [J04AC01or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Isoniazid (INH) 50 mg per tablet, oral ingestion tablet [J04AC01or]			NTP
Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules [J04AA01or]	HP, BHC, CHC, DH	DH, PH, RH	NTP
Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet [J04AK01or]			NTP
Pyrazinamide (PZA) 400 mg per tablet, oral ingestion tablet [J04AK01or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Pyrazinamide (PZA) 500 mg per tablet, oral ingestion tablet [J04AK01or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Rifampicin 150 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]	HSC, BHC, CHC, DH	DH, PH, RH	
Rifampicin 300 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]	HSC, MHT, BHC, CHC, DH	DH, PH, RH	
Rifampicin 150 mg + isoniazid 75 mg (RH) per tablet, oral ingestion tablet [J04AM02or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Rifampicin 150 mg + isoniazid 75 mg + ethambutol 275 mg (RHE) per tablet, oral ingestion tablet [J04AM07or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg (RHZE) per tablet, oral ingestion tablet or capsule [J04AM06or]			NTP

Category and Substance	BPHS	EPHS	Special Program
Rifampicin 60 mg + isoniazid 30 mg (RH) per tablet, oral ingestion tablet [J04AM02or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Rifampicin 60 mg + isoniazid 30 mg + pyrazinamide 150 mg (RHZ) per tablet, oral ingestion tablet [J04AM05or]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
Streptomycin (STM) 1 g per vial, injection vial [J04AB31inj]	HSC, BHC, CHC, DH	DH, PH, RH	NTP
J04B—Medicines for Treatment of Leptra			
Clofazimine (CLO) 100 mg per capsule, oral ingestion capsule [J04BA01or]		PH, RH	NLP
Clofazimine (CLO) 50 mg per capsule, oral ingestion capsule [J04BA01or]		PH, RH	NLP
Dapsone (DDS) 100 mg per tablet, oral ingestion tablet [J04BA02or]		PH, RH	NLP
Dapsone (DDS) 25 mg per tablet, oral ingestion tablet [J04BA02or]		PH, RH	NLP
Dapsone (DDS) 50 mg per tablet, oral ingestion tablet [J04BA02or]		PH, RH	NLP
Rifampicin 300 mg + dapsone 50 mg + clofazimine 50 mg per tablet, oral ingestion tablet [J04BA01or]		PH, RH	NLP
Rifampicin 600 mg + Dapsone 100 mg + Clofazimine 50 mg per tablet, oral ingestion tablet [J04BA01or]		PH, RH	NLP
J05—ANTIVIRALS FOR SYSTEMIC USE			
J05A—DIRECT-ACTING ANTIVIRALS			
Abacavir (ABC) 300 mg per tablet, oral ingestion tablet [J05AF06or]			HIV
Atazanavir 300 mg + ritonavir 100 mg (ATV/RTV) per tablet, oral ingestion tablet [J05AR12or]			HIV
Delavirdine 200 mg per tablet, oral ingestion tablet [J05AG02or]			
Efavirenz (EFV) 100 mg per capsule, oral ingestion capsule [J05AG03or]			HIV
Efavirenz (EFV) 150 mg/5 ml, oral ingestion liquid [J05AG03or]			HIV
Efavirenz (EFV) 200 mg per capsule, oral ingestion capsule [J05AG03or]			HIV
Efavirenz (EFV) 50 mg per capsule, oral ingestion capsule [J05AG03or]			HIV
Efavirenz (EFV) 600 mg per tablet, oral ingestion tablet [J05AG03or]			HIV
Efavirenz 600 mg + emtricitabine 200 mg + tenofovir 300 mg (EFV/FTC/TDF) per tablet, oral ingestion tablet [J05AR06or]			HIV
Emtricitabine (FTC) 200 mg per capsule, oral ingestion capsule [J05AF09or]			HIV
Emtricitabine (FTC) 50 mg/5 ml, oral ingestion liquid [J05AF09or]			HIV
Emtricitabine 200 mg + tenofovir 300 mg (FTC/TDF) per tablet, oral ingestion tablet [J05AR03or]			HIV

Category and Substance	BPHS	EPHS	Special Program
Enfuvirtide 108 mg per vial, injection powder [J05AX07inj]			HIV
Entecavir 0.5 mg per tablet, oral ingestion tablet [J05AF10or]			HIV
Etravirine 25 mg per tablet, oral ingestion tablet [J05AF10or]			HIV
Fosamprenavir 700 mg + ritonavir 100 mg (FPV/r) per tablet, oral ingestion tablet [J05AR13or]			
Indinavir (IDV) 200 mg per capsule, oral ingestion capsule [J05AE02or]			HIV
Indinavir (IDV) 333 mg per capsule, oral ingestion capsule [J05AE02or]			HIV
Indinavir (IDV) 400 mg per capsule, oral ingestion capsule [J05AE02or]			HIV
Indinavir 800 mg + ritonavir 100 mg (IDV/r) per tablet, oral ingestion tablet [J05AR11or]			HIV
Lamivudine (3TC) 100 mg per tablet, oral ingestion tablet [J05AF05or]			HIV
Lamivudine (3TC) 150 mg per tablet, oral ingestion tablet [J05AF05or]			HIV
Lamivudine (3TC) 300 mg per tablet, oral ingestion tablet [J05AF05or]			HIV
Lamivudine (3TC) 50 mg/5 ml, oral ingestion suspension [J05AF05or]			HIV
Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP) per tablet, oral ingestion tablet [J05AR05or]			HIV
Lamivudine 40 mg + stavudine 10 mg (d4T/3TC)/5 ml, oral solution [J05AR09or]			
Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR01or]			HIV
Lopinavir 133.3 mg + ritonavir 33.3 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or]			HIV
Lopinavir 200 mg + ritonavir 50 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or]			
Lopinavir 400 mg + ritonavir 100 mg (LPV/r)/5 ml, oral ingestion liquid [J05AR10or]			HIV
Maraviroc 150 mg per tablet, oral ingestion tablet [J05AX09or]			HIV
Maraviroc 300 mg per tablet, oral ingestion tablet [J05AX09or]			HIV
Nelfinavir (NFV) 200 mg/5 ml, oral ingestion suspension [J05AE04or]			HIV
Nelfinavir (NFV) 250 mg per tablet, oral ingestion tablet [J05AE04or]			HIV
Nelfinavir (NFV) 50 mg/g in 144 g pack, oral ingestion powder [J05AE04or]			HIV
Nelfinavir (NFV) 625 mg per tablet, oral ingestion tablet [J05AE04or]			HIV

Category and Substance	BPHS	EPHS	Special Program
Raltegravir 400 mg per tablet, oral ingestion tablet [J05AX08or]			HIV
Ritonavir (RTV) 100 mg per tablet, oral ingestion tablet [J05AE03or]			HIV
Ritonavir (RTV) 400 mg/5 ml, oral ingestion liquid [J05AE03or]			HIV
Saquinavir (SQV) 200 mg per capsule, oral ingestion capsule [J05AE01or]			HIV
Saquinavir 200 mg + ritonavir 500 mg (SQV/r) per tablet, oral ingestion tablet [J05AR08or]			
Stavudine 30 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]			
Stavudine 40 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]			
Zidovudine (AZT) 10 mg/ml, in 20 ml vial, injection solution [J05AF01inj]			HIV
Zidovudine (AZT) 100 mg per capsule, oral ingestion capsule [J05AF01or]			HIV
Zidovudine (AZT) 250 mg per capsule or tablet, oral ingestion capsule or tablet [J05AF01or]			HIV
Zidovudine (AZT) 300 mg per tablet, oral ingestion tablet [J05AF01or]			HIV
Zidovudine (AZT) 50 mg/5 ml, oral ingestion suspension [J05AF01or]			HIV
J06—IMMUNE SERA AND IMMUNOGLOBULINS			
J06A—Immune Sera			
Diphtheria antitoxin 10,000 IU per vial, injection vial [J06AA01inj]		PH, RH	
Diphtheria antitoxin 20,000 IU per vial, injection vial [J06AA01inj]		PH, RH	
Rabies antitoxin 150 mg/ml, in 1 ml, injection vial [J06AA06inj]		DH, PH, RH	
Scorpion antivenom in 5 ml, injection vial [J06AA20inj]		PH, RH	
J06B—IMMUNOGLOBULINS			
Anti-D immunoglobulin (human) 250 mcg per dose, in single dose vial, injection vial [J06BB01inj]		PH, RH	
Antitetanus immunoglobulin 250 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]	DH	DH, PH, RH	
Antitetanus immunoglobulin 1,500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]	DH	DH, PH, RH	
Antitetanus immunoglobulin 3,000 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]		PH, RH	
Antitetanus Immunoglobulin 500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]	DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
J07—VACCINES			
J07A—Bacterial Vaccines			
Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial [J07AF30inj]	HP, BHC, CHC, DH	DH, PH, RH, NH	
Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial [J07AL02inj]	HP, BHC, CHC, DH	DH, PH, RH	EPI
Pneumococcal conjugated vaccine 7-valent single dose per vial, injection vial [J07AL02inj]	HP, BHC, CHC, DH	DH, PH, RH	EPI
Tetanus toxoid vaccine 20 doses per vial, injection vial [J07AM01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
Tuberculosis vaccine (BCG) with diluent 20 doses per vial, injection vial [J07AN01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
J07B—VIRAL VACCINES			
Hepatitis B monovalent vaccine single dose (HepB) per milliliter, per vial, injection solution [J07BC01inj]	HP, BHC, CHC, DH	DH, PH, RH, NH	
Measles diluent 10 doses per vial, injection vial [J07BD01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Measles vaccine 10 doses per vial, injection vial [J07BD01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine [J07BF01or]	HP, BHC, CHC, DH	DH, PH, RH	EPI
Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine [J07BF01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
Oral polio vaccine–trivalent (OPV-T) 20 doses per vial, oral vaccine [J07BF02or]	HP, BHC, CHC, DH	DH, PH, RH	EPI
Rotavirus monovalent/pentavalent single or double dose in two vials, oral vaccine [J07BH01or]	HP, BHC, CHC, DH	DH, PH, RH	EPI
Rubella vaccine, live attenuated in single dose, injection vial [J07BJ01or]	HP, BHC, CHC, DH	DH, PH, RH	EPI
J07C—BACTERIAL AND VIRAL VACCINES, COMBINED			
Diphtheria, pertussis, tetanus, HepB, Hib vaccine 20 doses per vial, injection vial [J07CA03inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
Diphtheria, pertussis, tetanus, hepatitis B vaccine 10 doses per milliliter, injection vial [J07CA52inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	EPI
L—ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS			
L01—ANTINEOPLASTIC AGENTS			
L01B—Antimetabolites			
Fluorouracil 5% topical ointment [L01BC02]		RH	
L02—ENDOCRINE THERAPY			
L02A—Hormones and Related Agents			
Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [L02AA03or]		RH	

Category and Substance	BPHS	EPHS	Special Program
L04—IMMUNOSUPPRESSANTS			
L04A—IMMUNOSUPPRESSANTS			
Ciclosporin (cyclosporine) 100 mg/5 ml, oral ingestion solution [L04AD01or]			HIV
M—MUSCULOSKELETAL SYSTEM			
M01—ANTI-INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS			
M01A—Anti-Inflammatory and Antirheumatic Products, Nonsteroids			
Diclofenac (sodium or potassium) 50 mg per tablet, oral ingestion tablet [M01AB05or]	CHC, DH,	PH, RH	
Diclofenac (sodium or potassium) 25 mg/ml, in 3 ml ampoule, injection solution [M01AB05inj]	HSC, BHC, MHT, CHC, DH	PH, RH	
Ibuprofen 200 mg per tablet, oral ingestion tablet [M01AE01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Ibuprofen 400 mg per tablet, oral ingestion tablet [M01AE01or]	DH, PH, RH		
M01C—SPECIFIC ANTIRHEUMATIC AGENTS			
Methotrexate 2.5 mg per tablet, oral ingestion tablet [M01CX01or]			
Penicillamine 125 mg per tablet, oral ingestion tablet [M01CC01or]			
Penicillamine 250 mg per tablet, oral ingestion tablet [M01CC01or]			
Sulfasalazine 500 mg per tablet, oral ingestion tablet [M01CX02or]			
M03—MUSCLE RELAXANTS			
M03A—Muscle Relaxants, Peripherally Acting Agents			
Suxamethonium 50 mg/ml, in 2 ml ampoule, injection solution [M03AB01inj]		PH, RH	
M04—ANTIGOUT PREPARATIONS			
M04A—ANTIGOUT PREPARATIONS			
Allopurinol 100 mg per tablet, oral ingestion tablet [M04AA01or]		RH	
Colchicine 0.5 mg per tablet, oral ingestion tablet [M04AC01or]		RH	
N—NERVOUS SYSTEM			
N01—ANESTHETICS			
N01A—Anesthetics, General			
Halothane 250 ml, per bottle, inhalation solution [N01AB01]		RH	
Isoflurane in 250 ml, gas [N01AB06]	PH, RH		
Ketamine 50 mg/ml, in 10 ml vial, injection solution [N01AX03inj]	CHC, DH	DH, PH, RH	
Propofol 10 mg/ml, in 100 ml ampoule, infusion solution [N01AX10inj]		RH	

Category and Substance	BPHS	EPHS	Special Program
Propofol 10 mg/ml, in 20 ml, infusion solution [N01AX10inj]		PH, RH	
Thiopental sodium 1 g per vial, injection powder [N01AF03inj]		RH	
Thiopental sodium 500 mg per vial, injection powder [N01AF03inj]		RH	
N01B—Anesthetics, Local			
Adrenalin 0.0005% + lidocaine 1% injection solution [N01BB52inj]	CHC, DH	DH, PH, RH	
Adrenalin 0.0005% + lidocaine 2% in 50 ml vial, injection solution [N01BB52inj]	CHC, DH	DH, PH, RH	
Adrenalin 0.00125% + lidocaine dental 1% injection solution [N01BB52inj]	MHT, CHC, DH		
Adrenalin 0.00125% + lidocaine dental 2% injection solution [N01BB52inj]	MHT, CHC, DH	DH, PH, RH	
Bupivacaine 0.25% in 10 ml ampoule, injection solution [N01BB01inj]		PH, RH	
Bupivacaine 0.5% in 10 ml ampoule, injection solution [N01BB01inj]		PH, RH	
Glucose 7.5% + lidocaine 5% (lidocaine spinal) injection solution [N01BB52inj]	DH	DH, PH, RH	
Lidocaine 1% in 2 ml, injection vial [N01BB02inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Lidocaine 2% in 2 ml ampoule, injection solution [N01BB02inj]	HSC, MHT, BHC, BHC*, CHC, DH	DH, PH, RH	
N02—ANALGESICS			
N02A—Opioids			
Morphine (sulfate, hydrochloride) 10 mg/ml, in 1 ml ampoule, injection solution [N02AA01inj]	DH	DH, PH, RH	
Pethidine 100 mg per tablet, oral ingestion tablet [N02AB02or]		PH, RH	
Pethidine 50 mg/ml, injection solution [N02AB02inj]		PH, RH	
Pethidine 50 mg per tablet, oral ingestion tablet [N02AB02or]		PH, RH	
Tramadol 50 mg per capsule, oral ingestion capsule [N02AX02or]	DH,	DH, PH, RH	
Tramadol 50 mg/ml, in 2 ml, injection solution [N02AX02inj]	CHC, DH	DH, PH, RH	
N02B—Other Analgesics And Antipyretics			
Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [N02BA01or]	BHC, MHT, CHC, DH	DH, PH, RH	
Acetylsalicylic acid (aspirin) 300 mg per tablet, oral ingestion tablet [N02BA01or]		PH, RH	
Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [N02BA01or]		PH, RH,	

Category and Substance	BPHS	EPHS	Special Program
Acetylsalicylic acid (aspirin) 500 mg per tablet, oral ingestion tablet [N02BA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Paracetamol (acetaminophen) 100 mg/ml, in 15 ml bottle, oral ingestion drop [N02BE01or]		PH, RH	
Paracetamol (acetaminophen) 100 mg per tablet, oral ingestion tablet [N02BE01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Paracetamol (acetaminophen) 120 mg/5 ml, in 60 ml bottle, oral syrup [N02BE01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Paracetamol (acetaminophen) 125 mg per suppository, rectal suppository [N02BE01rec]	DH	DH, RH, DH,	
Paracetamol (acetaminophen) 325 mg per tablet, oral ingestion tablet [N02BE01or]	PH, RH		
Paracetamol (acetaminophen) 500 mg per tablet, oral ingestion tablet [N02BE01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
N02C—Antimigraine Preparations			
Ergotamine 1 mg per tablet, oral ingestion tablet [N02CA02or]		RH	
N03—ANTIEPILEPTICS			
N03A—Antiepileptics			
Carbamazepine 100 mg per tablet, oral ingestion tablet [N03AF01or]	CHC, DH	RH	
Carbamazepine 200 mg per tablet, oral ingestion tablet [N03AF01or]	CHC, DH	RH	
Ethosuximide 250 mg/5 ml, oral syrup [N03AD01or]		RH	
Ethosuximide 250 mg per capsule, oral ingestion capsule [N03AD01or]		RH	
Magnesium sulfate 500 mg/ml, in 10 ml ampoule, injection solution [N03AX31inj]	CHC, DH	DH, PH, RH	
Magnesium sulfate 500 mg/ml, in 20 ml ampoule, injection solution [N03AX31inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Magnesium sulfate 500 mg/ml, in 2 ml ampoule, injection solution [N03AX31inj]	CHC, DH	DH, RH, PH	
Phenobarbital 100 mg/ml, in 2 ml, injection solution [N03AA02inj]		PH, RH	
Phenobarbital 100 mg per tablet, oral ingestion tablet [N03AA02or]	BHC, MHT, CHC, DH	PH, RH	
Phenobarbital 15 mg per tablet, oral ingestion tablet [N03AA02or]	BHC, MHT, CHC, DH	PH, RH	
Phenobarbital 25 mg per tablet, oral ingestion tablet [N03AA02or]		PH, RH	
Phenobarbital 30 mg per tablet, oral ingestion tablet [N03AA02or]	DH	RH	
Phenobarbital 50 mg/ml, in 5 ml, injection solution [N03AA02inj]		PH, RH	

Category and Substance	BPHS	EPHS	Special Program
Phenobarbital 50 mg per tablet, oral ingestion tablet [N03AA02or]		DH, PH, RH	
Valproic acid (sodium valproate) 200 mg per tablet, oral ingestion tablet [N03AG01or]		RH	
Valproic acid (sodium valproate) 500 mg per tablet, oral ingestion tablet [N03AG01or]		RH	
N04—ANTI-PARKINSON MEDICINES			
N04A—Anticholinergic Agents			
Biperiden 2 mg per tablet, oral ingestion tablet [N04AA02or]		RH	
Biperiden 5 mg/ml, in 1 ml ampoule, injection solution [N04AA02inj]		RH	
Trihexyphenidyl 2 mg per tablet, oral ingestion tablet [N04AA01or]	CHC, DH	RH	
N04B—Dopaminergic Agents			
Bromocriptine mesylate 2.5 mg per tablet, oral ingestion tablet [N04BC01or]		RH	
Carbidopa 10 mg + levodopa 100 mg per tablet, oral ingestion tablet [N04BA02or]		RH	
Carbidopa 25 mg + levodopa 250 mg per tablet, oral ingestion tablet [N04BA02or]		RH	
N05—PSYCHOLEPTICS			
N05A—Antipsychotics			
Chlorpromazine 25 mg per tablet, oral ingestion tablet [N05AA01or]		PH, RH	
Chlorpromazine 100 mg per tablet, oral ingestion tablet [N05AA01or]	DH	DH, PH, RH	
Chlorpromazine 25 mg/ml, in 2 ml ampoule, injection solution [N05AA01inj]	DH	DH, PH, RH	
Fluphenazine (oily) 1 mg/ml, in 1 ml ampoule, injection solution [N05AB02inj]			
Haloperidol 2 mg per tablet, oral ingestion tablet [N05AD01or]		PH, RH	
Haloperidol 5 mg/ml, in 1 ml, injection solution [N05AD01inj]	DH	DH, PH, RH	
Haloperidol 5 mg per tablet, oral ingestion tablet [N05AD01or]	DH	DH, PH, RH	
N05B—Anxiolytics			
Alprazolam 0.5 mg per tablet, oral ingestion tablet [N05BA12or]		PH, RH	
Chlordiazepoxide 10 mg per tablet, oral ingestion tablet [N05BA02or]			
Diazepam 10 mg per tablet, oral ingestion tablet [N05BA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Diazepam 2 mg per tablet, oral ingestion tablet [N05BA01or]		PH, RH	

Category and Substance	BPHS	EPHS	Special Program
Diazepam 5 mg/ml, in 2 ml, injection solution [N05BA01inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Diazepam 5 mg per tablet, oral ingestion tablet [N05BA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
N05C—Hypnotics and Sedatives			
Midazolam 1 mg/ml, in 1 ml ampoule, injection solution [N05CD08inj]		DH, RH, PH,	
N06—PSYCHOANALEPTICS			
N06A—Antidepressants			
Amitriptyline 25 mg per tablet, oral ingestion tablet [N06AA09or]	CHC, DH	DH, PH, RH	
Clomipramine 25 mg per tablet, oral ingestion tablet [N06AA04or]		PH, RH	
Clomipramine 50 mg per tablet, oral ingestion tablet [N06AA04or]	CHC, DH		
Fluoxetine 20 mg per capsule, oral ingestion capsule [N06AB03or]	DH	DH, PH, RH	
Imipramine 10 mg per tablet, oral ingestion tablet [N06AA02or]		DH, PH, RH	
Imipramine 25 mg per tablet, oral ingestion tablet [N06AA02or]		DH, PH, RH	
Nortriptyline 10 mg per tablet, oral ingestion tablet [N06AA10or]			
N07—OTHER NERVOUS SYSTEM MEDICINES			
N07A—Parasympathomimetics			
Neostigmine bromide 15 mg per tablet, oral ingestion tablet [N07AA01or]	DH	DH, PH, RH	
Neostigmine methylsulfate 0.5 mg/ml, in 10 ml, injection solution [N07AA01inj]	DH	DH, PH, RH	
N07B—Medicines Used in Addictive Disorders			
Buprenorphine 2 mg per tablet, oral ingestion tablet [N07BC01or]			NDDR
Buprenorphine 8 mg per tablet, oral ingestion tablet [N07BC01or]			NDDR
Methadone 10 mg/ml per milliliter, in 1 ml ampoule, injection solution [N07BC02inj]			NDDR
Methadone 10 mg/ml, oral solution [N07BC02or]			NDDR
Methadone 10 mg per tablet, oral ingestion tablet [N07BC02or]			NDDR
Methadone 5 mg/ml, oral solution [N07BC02or]			NDDR
Methadone 5 mg per tablet, oral ingestion tablet [N07BC02or]			NDDR
Opium tincture 10% oral solution [N07BC59or]			NDDR

Category and Substance	BPHS	EPHS	Special Program
P—ANTIPARASITIC PRODUCTS, INSECTICIDES, AND REPELLENTS			
P01—ANTIPROTOZOALS			
P01A—Agents Against Amebiasis And Other Protozoal Diseases			
Metronidazole 200 mg/5 ml, in 60 ml bottle, oral ingestion suspension [P01AB01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Metronidazole 200 mg per tablet, oral ingestion tablet [P01AB01or]	HSC, BHC, MHT, CHC, DH		
Metronidazole 250 mg per tablet, oral ingestion tablet [P01AB01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Metronidazole 400 mg per tablet, oral ingestion tablet [P01AB01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Metronidazole 500 mg per tablet, oral ingestion tablet [P01AB01or]	HSC, BHC, MHT, CHC, DH	DH, RH, PH,	
P01B—Antimalarials			
Artemether oily 20 mg/ml, injection solution [P01BE02inj]		PH, RH	NMLP
Artemether oily 40 mg/ml, injection solution [P01BE02inj]		PH, RH	NMLP
Artemether oily 80 mg/ml, injection solution [P01BE02inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
Artesunate 100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blister), oral ingestion tablet [P01BF04or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
Artesunate 300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet [P01BF04or]	BHC, CHC, DH	DH, PH, RH	NMLP
Artesunate 50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet [P01BF04or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
Artesunate 600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet [P01BF04or]	BHC, CHC, DH	DH, PH, RH	NMLP
Chloroquine (base) 150 mg per tablet, oral ingestion tablet [P01BA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
Chloroquine (base) 50 mg/ml, in 60 ml, oral syrup [P01BA01or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
Primaquine 15 mg per tablet, oral ingestion tablet [P01BA03or]	CHC, DH	DH, RH, PH,	NMLP
Primaquine 7.5 mg per tablet, oral ingestion tablet [P01BA03or]	CHC, DH	DH, RH, PH,	NMLP
Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution [P01BC01inj]	CHC, DH	DH, PH, RH	NMLP

Category and Substance	BPHS	EPHS	Special Program
Quinine sulfate 300 mg per tablet, oral ingestion tablet [P01BC01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	NMLP
P01C—Agents Against Leishmaniasis and Trypanosomiasis			
Meglumine antimoniate 30% in 5 ml ampoule, injection solution [P01CB01inj]	CHC, DH	DH, PH, RH	NMLP
Sodium stibogluconate 100 mg/ml, injection solution [P01CB02inj]	CHC, DH	DH, PH, RH	NMLP
P02—ANTHELMINTICS			
P02C—Antinematodal Agents			
Albendazole 200 mg per tablet, oral chewable tablet [P02CA03or]	DH	DH, PH, RH	
Albendazole 400 mg per tablet, oral chewable tablet [P02CA03or]	DH	DH, PH, RH	
Mebendazole 100 mg per tablet, oral chewable tablet [P02CA01or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
P02D—Anticestodals			
Niclosamide 500 mg per tablet, oral ingestion chewable tablet [P02DA01or]	BHC, CHC, DH	DH, PH, RH,	
P03—ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES, AND REPELLENTS			
P03A—Ectoparasiticides, Including Scabicides			
Benzoic acid 6% + salicylic acid 3% topical ointment [P03AX01]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Benzyl benzoate 25% in 60 ml bottle, topical lotion [P03AX01]	BHC, CHC, DH,	DH, PH, RH,	
Lindane 1% topical shampoo [P03AB02]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Permethrin 1% in 60 ml bottle, topical lotion [P03AC04]	BHC, CHC, DH,	DH	
Permethrin 5% in 30 g tube, topical cream [P03AC04]	BHC, CHC, DH,	DH, PH, RH,	
R—RESPIRATORY SYSTEM			
R01—NASAL PREPARATIONS			
R01A—Decongestants and Other Nasal Preparations for Topical Use			
Naphazoline 0.05% in 10 ml bottle, nasal drop [R01AA08]		PH, RH	
Sodium chloride 0.65% in 10 ml, nasal drop [R01AX30]	BHC, CHC, DH,	DH, PH, RH,	
R03—MEDICINES FOR OBSTRUCTIVE AIRWAY DISEASES			
R03A—Adrenergics, Inhalants			
Salbutamol 0.1 mg per dose, in 200-dose bottle, inhalation solution [R03AC02]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Salbutamol 5 mg/ml, nebulizer solution [R03AC02]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
R03B—Other Medicines for Obstructive Airway Diseases, Inhalants			
Beclometasone dipropionate 250 mcg per dose, inhalation aerosol [R03BA01]		PH, RH	
Beclometasone dipropionate 50 mcg per dose, inhalation aerosol [R03BA01]		PH, RH	
R03C—Adrenergics for Systemic Use			
Salbutamol 0.05 mg/ml, in 5 ml ampoule, injection ampoule [R03CC02inj]		RH	
Salbutamol 0.5 mg/ml, in 1 ml ampoule, injection ampoule or vial [R03CC02inj]		RH	
Salbutamol 2 mg/5 ml, in 60 ml bottle, oral syrup [R03CC02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Salbutamol 2 mg per tablet, oral ingestion tablet [R03CC02or]		PH, RH	
Salbutamol 4 mg per tablet, oral ingestion tablet [R03CC02or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
R03D—Other Systemic Medicines for Obstructive Airway Diseases			
Aminophylline 100 mg per tablet, oral ingestion tablet [R03DA05or]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Aminophylline 25 mg/ml, in 10 ml ampoule, injection solution [R03DA05inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
R06—ANTIHISTAMINES FOR SYSTEMIC USE			
R06A—Antihistamines for Systemic Use			
Chlorphenamine maleate 10 mg/ml, in 1 ml, injection solution [R06AB04inj]	HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Chlorphenamine maleate 4 mg per tablet, oral ingestion tablet [R06AB04or]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Dimenhydrinate 50 mg per tablet, oral ingestion tablet [R06AA52or]		RH	
Diphenhydramine chloride 25 mg per tablet, oral ingestion tablet [R06AA02or]		DH, PH, RH	
Diphenhydramine chloride 50 mg per tablet, oral ingestion tablet [R06AA02or]		DH, PH, RH	
Diphenhydramine chloride 5 mg/5 ml, in 60 ml, oral syrup [R06AA02or]		DH, PH, RH	
Diphenhydramine teoclate 50 mg per tablet, oral ingestion tablet [R06AA02or]		RH	
Promethazine 25 mg/ml, in 2 ml ampoule, injection solution [R06AD02inj]		RH	
Promethazine 25 mg per tablet, oral ingestion tablet [R06AD02or]		RH	
Promethazine 5 mg/5 ml, oral syrup [R06AD02or]		RH	

Category and Substance	BPHS	EPHS	Special Program
S—SENSORY ORGANS			
S01—OPHTHALMOLOGICALS			
S01a—Eye Anti-Infectives			
Aciclovir 3% in 5 g tube, ophthalmic ointment [S01AD03]		PH, RH	
Chloramphenicol 0.5% in 2.5 ml bottle, ophthalmic drop [S01AA01]		PH, RH	
Gentamicin 0.3% in 5 ml bottle, ophthalmic drop [S01AA11]		RH	
Neomycin sulfate 0.5% in 15 g tube, topical cream [S01AA03]	DH,	DH, PH, RH,	
Sulfacetamide 10% in 15 ml bottle, ophthalmic drop [S01AB04]		RH	
Sulfacetamide 20% in 15 ml bottle, ophthalmic drop [S01AB04]		RH	
Tetracycline 1% in 5g, ophthalmic ointment [S01AA09]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
S01B—Eye Anti-Inflammatory Agents			
Prednisolone 0.5% in 5 ml bottle, ophthalmic drop [S01BA04]		RH	
Prednisolone 1% in 5 ml bottle, ophthalmic drop [S01BA04]			
S01E—Antiglaucoma Preparations and Miotics			
Acetazolamide 250 mg per tablet, oral ingestion tablet [S01EC01or]		RH	
Pilocarpine 2% in 15 ml bottle, ophthalmic drop [S01EB01]		RH	
Pilocarpine 4% in 15 ml bottle, ophthalmic drop [S01EB01]		RH	
Timolol 0.25% in 5 ml bottle, ophthalmic drop [S01ED01]		RH	
Timolol 0.5% in 5 ml bottle, ophthalmic drop [S01ED01]		RH	
S01F—Mydriatics and Cycloplegics			
Atropine sulfate 0.1% in 5 ml bottle, ophthalmic drop [S01FA01]		RH	
Atropine sulfate 0.5% in 5 ml bottle, ophthalmic drop [S01FA01]		RH	
Atropine Sulfate 1% in 5 ml bottle, ophthalmic drop [S01FA01]		RH	
Tropicamide 0.5% in 15 ml bottle, ophthalmic drop [S01FA06]		RH	
Tropicamide 1% in 3 ml bottle, ophthalmic drop [S01FA06]		RH	
S01H—Eye Local Anesthetics			
Tetracaine 0.5% in 15 ml bottle, ophthalmic drop [S01HA03]	CHC, DH	PH, RH	

Category and Substance	BPHS	EPHS	Special Program
S02—OTOLOGICALS			
S02A—Ear Anti-Infectives			
Boric acid + glycerin 5% (glycerin boric) otic liquid [S02AA03]		RH	
V—VARIOUS			
V03—ALL OTHER THERAPEUTIC PRODUCTS			
V03A—All Other Therapeutic Products			
Acetylcysteine 200 mg/ml, in 10 ml ampoule, injection solution [V03AB23or]		RH	
Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [V03AB29or]	CHC, DH	DH, PH, RH	
Deferoxamine mesylate 500 mg per vial, injection powder [V03AC01inj]		RH	
Dimercaprol (BAL) 100 mg/ml, in 3 ml ampoule, injection solution [V03AB09inj]		RH	
Dimercaprol (BAL) 50 mg/ml, in 2 ml ampoule, injection solution [V03AB09inj]		RH	
Flumazenil 0.1 mg/ml, in 10 ml, injection solution [V03AB25inj]	DH	DH, PH, RH	
Methylene blue (methylthionium) 10 mg/ml, in 10 ml ampoule, injection solution [V03AB17inj]		RH	
Naloxone 400 mcg/ml, in 1 ml, injection solution [V03AB15or]	DH	DH, PH, RH	
Oxygen inhalation gas [V03AN01]	HSC, BHC, CHC, DH	DH, PH, RH	
Potassium iodide 60 mg per tablet, oral ingestion tablet [V03AB21or]		RH	
Pralidoxime 500 mg/ml, injection solution [V03AB04inj]		PH, RH,	
Protamine sulfate 10 mg/ml, in 5 ml ampoule, injection solution [V03AB14inj]		PH, RH	
V04—DIAGNOSTIC AGENTS			
V04C—Other Diagnostic Agents			
Tuberculin purified protein derivative 100 IU/ml, injection solvent [V04CF01]		PH, RH	
Tuberculin purified protein derivative 10 IU/ml, injection solvent [V04CF01]		DH, PH, RH	
V07—ALL OTHER NONTHERAPEUTIC PRODUCTS			
V07A—All Other Nontherapeutic Products			
Water for injection per milliliter, in 10 ml ampoule, injection solution [V07AB01inj]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	
Water for injection per milliliter, in 5 ml ampoule, injection solution [V07AB01inj]	HP, HSC, BHC, MHT, CHC, DH	DH, PH, RH	

Category and Substance	BPHS	EPHS	Special Program
V08—CONTRAST MEDIA			
V08A—X-Ray Contrast Media, Iodinated			
Diatrizoic acid (amidotrizoate) 420 mg/ml, injection solution [V08AA01inj]			
Diatrizoic acid meglumine 66% + diatrizoic acid sodium 10% (Urografin76™) injection solution [V08AA01inj]		RH	
V08B—X-Ray Contrast Media, Non-Iodinated			
Barium sulfate 30% parenteral aqueous solution [V08BA01]		PH, RH	
V99—UNCLASSIFIED			
V99A—Dental and Dispensary Items			
Vaseline [V99AB00]			Disp.

Essential Medicines List Alphabetical Index

A

Abacavir (ABC) 300 mg per tablet, oral ingestion tablet [J05AF06or] → **See: National HIV/AIDS**

Program List

- Acetazolamide 250 mg per tablet, oral ingestion tablet [S01EC01or]
 Acetylcysteine 200 mg/ml, in 10 ml ampoule, injection ampoule [V03AB23inj]
 Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [B01AC06or]
 Acetylsalicylic acid (aspirin) 100 mg per tablet, oral ingestion tablet [N02BA01or]
 Acetylsalicylic acid (aspirin) 300 mg per tablet, oral ingestion tablet [N02BA01or]
 Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [N02BA01or]
 Acetylsalicylic acid (aspirin) 325 mg per tablet, oral ingestion tablet [B01AC06or]
 Acetylsalicylic acid (aspirin) 500 mg per tablet, oral ingestion tablet [N02BA01or]
 Aciclovir 3% in 5 g tube, ophthalmic ointment [S01AD03]
 Activated charcoal 1 g per tablet, oral ingestion tablet [A07BA01or]
 Activated charcoal 500 mg per tablet, oral ingestion tablet [A07BA01or]
 Adrenalin 0.0005% + lidocaine 1% injection solution [N01BB52inj]
 Adrenalin 0.0005% + lidocaine 2% in 50 ml vial, injection solution [N01BB52inj]
 Adrenalin 0.00125% + lidocaine dental 1% injection solution [N01BB52inj]
 Adrenalin 0.00125% + lidocaine dental 2% injection solution [N01BB52inj]
 Albendazole 200 mg per tablet, oral chewable tablet [P02CA03or]
 Albendazole 400 mg per tablet, oral chewable tablet [P02CA03or]
 Allopurinol 100 mg per tablet, oral ingestion tablet [M04AA01or]
 Alprazolam 0.5 mg per tablet, oral ingestion tablet [N05BA12or]
 Aluminium hydroxide 120 mg + magnesium trisilicate 250 mg per tablet, oral ingestion tablet [A02AD01or]
 Aluminium hydroxide 200 mg + magnesium hydroxide 200 mg per tablet, oral chewable tablet [A02AD01or]
 Aluminium hydroxide 225 mg + magnesium hydroxide 200 mg/5 ml, in 200 ml bottle, oral ingestion suspension [A02AD01or]
 Aluminium hydroxide 500 mg per tablet, oral chewable tablet [A02AB01or]
 Amikacin 500 mg/ml, in 2 ml vial, injection vial [J01GB06inj]
 Aminophylline 100 mg per tablet, oral ingestion tablet [R03DA05or]
 Aminophylline 25 mg/ml, in 10 ml ampoule, injection solution [R03DA05inj]
 Amitriptyline 25 mg per tablet, oral ingestion tablet [N06AA09or]
 Amlodipine 5 mg per tablet, oral ingestion tablet [C08CA01or]
 Amoxicillin 125 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]
 Amoxicillin 125 mg + clavulanic acid 31.25 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CR02or]
 Amoxicillin 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01CA04or]
 Amoxicillin 250 mg per tablet, oral ingestion tablet [J01CA04or]
 Amoxicillin 500 mg per tablet, oral ingestion tablet [J01CA04or]
 Amoxicillin 500 mg + clavulanic acid 125 mg (co-amoxiclav) per tablet, oral ingestion tablet [J01CR02or]
 Ampicillin 1 g per vial, injection powder [J01CA01inj]
 Ampicillin 500 mg per vial, injection powder [J01CA01inj]
 Anti-D immunoglobulin (human) 250 mcg per dose, in single-dose vial, injection vial [J06BB01inj]
 Antitetanus immunoglobulin 250 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]
 Antitetanus immunoglobulin 1,500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]
 Antitetanus immunoglobulin 3,000 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]
 Antitetanus immunoglobulin 500 IU/ml, in 1 ml ampoule, injection solution [J06BB02inj]

- Artemether (oily) 20 mg/ml, injection solution [P01BE02inj] → **See: National Malaria and Leishmania Control Program List**
- Artemether (oily) 40 mg/ml, injection solution [P01BE02inj] → **See: National Malaria and Leishmania Control Program List**
- Artemether (oily) 80 mg/ml, injection solution [P01BE02inj] → **See: National Malaria and Leishmania Control Program List**
- Artesunate 100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blister), oral ingestion tablet [P01BF04or] → **See: National Malaria and Leishmania Control Program List**
- Artesunate 300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet [P01BF04or] → **See: National Malaria and Leishmania Control Program List**
- Artesunate 50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet [P01BF04or] → **See: National Malaria and Leishmania Control Program List**
- Artesunate 600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet [P01BF04or] → **See: National Malaria and Leishmania Control Program List**
- Atazanavir 300 mg + ritonavir 100 mg (ATV/RTV) per tablet, oral ingestion tablet [J05AR12or] → **See: National HIV/AIDS Program List**
- Atenolol 25 mg per tablet, oral ingestion tablet [C07AB03or]
- Atenolol 50 mg per tablet, oral ingestion tablet [C07AB03or]
- Atenolol 100 mg per tablet, oral ingestion tablet [C07AB03or]
- Atorvastatin 20 mg per tablet, oral ingestion tablet [C10AA05or]
- Atropine sulfate 0.5% in 5 ml bottle, ophthalmic drop [S01FA01]
- Atropine sulfate 1% in 5 ml bottle, ophthalmic drop [S01FA01]
- Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [A03BA01inj]
- Atropine sulfate 1 mg/ml, in 1 ml ampoule, injection solution [V03AB29inj]
- Atropine sulfate 1 mg per tablet, oral ingestion tablet [A03BA01or]
- Azithromycin 250 mg per capsule, oral ingestion capsule [J01FA10or]
- Azithromycin 500 mg per capsule, oral ingestion capsule [J01FA10or]

B

- Bacitracin 500 IU + neomycin 5 mg/g, in 15 g tube, topical ointment [D06AX51]
- Barium sulfate 30% parenteral aqueous solution [V08BA01]
- Beclometasone dipropionate 250 mcg per dose, inhalation aerosol [R03BA01ihas]
- Beclometasone dipropionate 50 mcg per dose, inhalation aerosol [R03BA01ihas]
- Benzoic acid 6% + salicylic acid 3% topical ointment [P03AX01]
- Benzoyl peroxide 5% topical cream [D10AE01]
- Benzoyl peroxide 5% topical lotion [D10AE01]
- Benzyl benzoate 25% in 60 ml bottle, topical lotion [P03AX01]
- Betamethasone 0.1% + neomycin 0.5% in 15 g tube, topical cream [D07CC01]
- Biperiden 2 mg per tablet, oral ingestion tablet [N04AA02or]
- Biperiden 5 mg/ml, in 1 ml ampoule, injection solution [N04AA02inj]
- Bisacodyl 5 mg per tablet, oral ingestion tablet [A06AB02or]
- Boric acid + glycerin 5% (glycerin boric) in 10 ml, topical solution [D08AD01]
- Boric acid + glycerin 5% (glycerin boric) otic liquid [S02AA03]
- Bromocriptine mesylate 2.5 mg per tablet, oral ingestion tablet [N04BC01or]
- Bupivacaine 0.25% in 10 ml ampoule, injection solution [N01BB01inj]
- Bupivacaine 0.5% in 10 ml ampoule, injection solution [N01BB01inj]
- Buprenorphine 2 mg per tablet, oral ingestion tablet [N07BC01or] → **See: National Drug Dependency Reduction Program**
- Buprenorphine 8 mg per tablet, oral ingestion tablet [N07BC01or] → **See: National Drug Dependency Reduction Program**

C

- Calamine (ZnO + Fe₂O₃) 8% in 30 g tube, topical cream [D04AX01]
- Calamine (ZnO + Fe₂O₃) 8% in 60 ml bottle, topical lotion [D04AX01]
- Calcium gluconate 10% in 10 ml ampoule, injection solution [A12AA03inj]
- Capreomycin 1 g per vial, injection powder [J04AB30inj] → **See: National Tuberculosis Program List**
- Captopril 25 mg per tablet, oral ingestion tablet [C09AA01or]
- Carbamazepine 100 mg per tablet, oral ingestion tablet [N03AF01or]
- Carbamazepine 200 mg per tablet, oral ingestion tablet [N03AF01or]
- Carbidopa 10 mg + levodopa 100 mg per tablet, oral ingestion tablet [N04BA02or]
- Carbidopa 25 mg + levodopa 250 mg per tablet, oral ingestion tablet [N04BA02or]
- Carbimazole 5 mg per tablet, oral ingestion tablet [H03BB01or]
- Ceftriaxone 1 g per vial, injection powder [J01DD04inj]
- Ceftriaxone 500 mg per vial, injection powder [J01DD04inj]
- Cetrimide 15% + chlorhexidine gluconate 1.5% topical solution [D08AC52]
- Chloramphenicol 0.5% in 2.5 ml bottle, ophthalmic drop [S01AA01]
- Chloramphenicol 125 mg/5 ml, in 100 ml bottle, oral syrup [J01BA01or]
- Chloramphenicol 1 g per vial, injection powder [J01BA01inj]
- Chloramphenicol 250 mg per capsule, oral ingestion capsule [J01BA01or]
- Chloramphenicol 500 mg per vial, injection powder [J01BA01inj]
- Chlordiazepoxide 10 mg per tablet, oral ingestion tablet [N05BA02or]
- Chlorhexidine digluconate 5% topical solution [D08AC02]
- Chlorhexidine digluconate 7.1% topical solution or gel solution [D08AC02]
- Chloroquine (base) 150 mg per tablet, oral ingestion tablet [P01BA01or] → **See: National Malaria and Leishmania Control Program List**
- Chloroquine (base) 50 mg/5 ml, in 60 ml, oral syrup [P01BA01or] → **See: National Malaria and Leishmania Control Program List**
- Chlorphenamine maleate 10 mg/ml, in 1 ml, injection solution [R06AB04inj]
- Chlorphenamine maleate 4 mg per tablet, oral ingestion tablet [R06AB04or]
- Chlorpromazine 25 mg per tablet, oral ingestion tablet [N05AA01or]
- Chlorpromazine 100 mg per tablet, oral ingestion tablet [N05AA01or]
- Chlorpromazine 25 mg/ml, in 2 ml ampoule, injection solution [N05AA01inj]
- Colecalciferol (vit D₃) 600,000 IU/ml, injection solution [A11CC05inj]
- Ciclosporin (cyclosporine) 100 mg/5 ml, oral ingestion solution [L04AD01or]
- Ciprofloxacin 250 mg per tablet, oral ingestion tablet [J01MA02or]
- Ciprofloxacin 2 mg/ml, in 50 ml ampoule, infusion solution [J01MA02inj]
- Ciprofloxacin 500 mg per tablet, oral ingestion tablet [J01MA02or]
- Clindamycin 150 mg per capsule, oral ingestion capsule [J01FF01or]
- Clindamycin 900 mg + dextrose 5% in 50 ml, parenteral infusion [J01FF01inj]
- Clofazimine (CLO) 100 mg per capsule, oral ingestion capsule [J04BA01or] → **See: National Leprosy Program List**
- Clofazimine (CLO) 50 mg per capsule, oral ingestion capsule [J04BA01or] → **See: National Leprosy Program List**
- Clomifene 50 mg per tablet, oral ingestion tablet [G03GB02or]
- Clomipramine 25 mg per tablet, oral ingestion tablet [N06AA04or]
- Clomipramine 50 mg per tablet, oral ingestion tablet [N06AA04or]
- Cloxacillin 250 mg per capsule, oral ingestion capsule [J01CF02or]
- Cloxacillin 500 mg per capsule, oral ingestion capsule [J01CF02or]
- Cloxacillin 500 mg per vial, injection powder [J01CF02inj]

Coagulation factor II, VII, IX, X per ampoule, injection solution [B02BD01inj]
 Coagulation factor VIII per ampoule, injection solution [B02BD02inj]
 Coal tar 5% in 100 g bottle, topical lotion [D05AA01]
 Colchicine 0.5 mg per tablet, oral ingestion tablet [M04AC01or]
 Colestyramine (cholestyramine) 4 g per sachet, oral ingestion powder [C10AC01or]
 Condom with and without nonoxinol 1 pce per piece, topical [G02BX01] → **See: National Family Planning Program List**
 Cycloserine 250 mg per capsule, oral ingestion capsule [J04AB01or] → **See: National Tuberculosis Program List**

D

Dapsone (DDS) 100 mg per tablet, oral ingestion tablet [J04BA02or] → **See: National Leprosy Program List**
 Dapsone (DDS) 25 mg per tablet, oral ingestion tablet [J04BA02or] → **See: National Leprosy Program List**
 Dapsone (DDS) 50 mg per tablet, oral ingestion tablet [J04BA02or] → **See: National Leprosy Program List**
 Deferoxamine mesylate 500 mg per vial, injection powder [V03AC01inj]
 Delavirdine 200 mg per tablet, oral ingestion tablet [J05AG02or]
 Dextran 70 6% injection solution [B05AA05inj]
 Diatrizoic acid (amidotrizoate) 420 mg/ml, injection solution [V08AA01inj]
 Diatrizoic acid meglumine 66% + diatrizoic acid sodium 10% (Urografin 76™) injection solution [V08AA01inj]
 Diazepam 10 mg per tablet, oral ingestion tablet [N05BA01or]
 Diazepam 2 mg per tablet, oral ingestion tablet [N05BA01or]
 Diazepam 5 mg/ml in 2 ml, injection solution [N05BA01inj]
 Diazepam 5 mg per tablet, oral ingestion tablet [N05BA01or]
 Diclofenac (sodium or potassium) 50 mg per tablet, oral ingestion tablet [M01AB05or]
 Diclofenac (sodium or potassium) 25 mg/ml, in 3 ml ampoule, injection solution [M01AB05inj]
 Digoxin 0.25 mg/ml, in 2 ml ampoule, injection solution [C01AA05inj]
 Digoxin 0.25 mg per tablet, oral ingestion tablet [C01AA05or]
 Dimenhydrinate 50 mg per tablet, oral ingestion tablet [R06AA52or]
 Dimercaprol (BAL) 100 mg/ml, in 3 ml ampoule, injection solution [V03AB09inj]
 Dimercaprol (BAL) 50 mg/ml, in 2 ml ampoule, injection solution [V03AB09inj]
 Diphenhydramine chloride 25 mg per tablet, oral ingestion tablet [R06AA02or]
 Diphenhydramine chloride 50 mg per tablet, oral ingestion tablet [R06AA02or]
 Diphenhydramine chloride 5 mg/5 ml, in 60 ml, oral syrup [R06AA02or]
 Diphenhydramine teoclate 50 mg per tablet, oral ingestion tablet [R06AA02or]
 Diphtheria antitoxin 10,000 IU per vial, injection vial [J06AA01inj]
 Diphtheria antitoxin 20,000, IU per vial, injection vial [J06AA01inj]
 Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial [J07AF30inj]
 Diphtheria, pertussis, tetanus, hepatitis B vaccine 10 doses per milliliter, injection vial [J07CA52inj]
 Diphtheria, pertussis, tetanus, HepB, Hib vaccine 20 doses per vial, injection vial [J07CA03inj]
 Dopamine 40 mg/ml, in 5 ml vial, injection solution [C01CA04inj]
 Doxycycline 100 mg per capsule, oral ingestion capsule [J01AA02or]

E

Efavirenz (EFV) 100 mg per capsule, oral ingestion capsule [J05AG03or] → **See: National HIV/AIDS Program List**
 Efavirenz (EFV) 150 mg/5 ml, oral ingestion liquid [J05AG03or] → **See: National HIV/AIDS Program List**
 Efavirenz (EFV) 200 mg per capsule, oral ingestion capsule [J05AG03or] → **See: National HIV/AIDS Program List**

- Efavirenz (EFV) 50 mg per capsule, oral ingestion capsule [J05AG03or] → **See: National HIV/AIDS Program List**
- Efavirenz (EFV) 60 mg per capsule, oral ingestion capsule [J05AG03or] → **See: National HIV/AIDS Program List**
- Efavirenz 600 mg + emtricitabine 200 mg + tenofovir 300 mg (EFV/FTC/TDF) per tablet, oral ingestion tablet [J05AR06or] → **See: National HIV/AIDS Program List**
- Emtricitabine (FTC) 200 mg per capsule, oral ingestion capsule [J05AF09or] → **See: National HIV/AIDS Program List**
- Emtricitabine (FTC) 50 mg/5 ml, oral ingestion liquid [J05AF09or] → **See: National HIV/AIDS Program List**
- Emtricitabine 200 mg + tenofovir 300 mg (FTC/TDF) per tablet, oral ingestion tablet [J05AR03or] → **See: National HIV/AIDS Program List**
- Enalapril 10 mg per tablet, oral ingestion tablet [C09AA02or]
- Enfuvirtide 108 mg per vial, injection powder [J05AX07or] → **See: National HIV/AIDS Program List**
- Enoxaparin 100 mg/ml, in 1 ml ampoule, injection solution [B01AB05inj]
- Entecavir 0.5 mg per tablet, oral ingestion tablet [J05AF10or] → **See: National HIV/AIDS Program List**
- Etravirine 25 mg per tablet, oral ingestion tablet [J05AF10or] → **See: National HIV/AIDS Program List**
- Epinephrine (adrenaline) 0.1% in 1 ml ampoule, injection solution [C01CA24inj]
- Ergometrine maleate 0.2 mg/ml, injection solution [G02AB03inj]
- Ergometrine maleate 0.2 mg per tablet, oral ingestion tablet [G02AB03or]
- Ergotamine 1 mg per tablet, oral ingestion tablet [N02CA02or]
- Erythromycin (base) 125 mg/5 ml, in 60 ml, oral ingestion suspension [J01FA01or]
- Erythromycin (ethylsuccinate) 200 mg per tablet, oral ingestion tablet [J01FA01or]
- Erythromycin (ethylsuccinate) 400 mg per tablet, oral ingestion tablet [J01FA01or]
- Erythromycin stearate 250 mg per tablet, oral ingestion tablet [J01FA01or]
- Erythromycin stearate 500 mg per tablet, oral ingestion tablet [J01FA01or]
- Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet [J04AK02or] → **See: National Tuberculosis Program List**
- Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet [J04AK02or] → **See: National Tuberculosis Program List**
- Ethambutol 400 mg + isoniazid 150 mg (EH) per tablet, oral ingestion tablet [J04AK02or] → **See: National Tuberculosis Program List**
- Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet [J04AM03or] → **See: National Tuberculosis Program List**
- Ethambutol 275 mg (E) + isoniazid 75 mg (H) + pyrazinamide 400 mg (Z) + rifampicin (R) 150 mg (RHZE) per tablet, oral ingestion tablet [J04AM06or] → **See: National Tuberculosis Program List**
- Ethinylestradiol 0.01 mg per tablet, oral ingestion tablet [G03CA01or]
- Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet [G03AA05or] → **See: National Family Planning Program List**
- Ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per tablet, oral ingestion tablet [G03AA07or]
- Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet [G03AA06or] → **See: National Family Planning Program List**
- Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [L02AA03or]
- Ethinylestradiol 0.05 mg per tablet, oral ingestion tablet [G03CA01or]
- Ethinylestradiol 0.05 mg + levonorgestrel 0.25 mg per tablet, oral ingestion tablet [G03AA07or]
- Ethionamide 250 mg per tablet, oral ingestion tablet [J04AD03or] → **See: National Tuberculosis Program List**
- Ethosuximide 250 mg/5 ml, oral syrup [N03AD01or]
- Ethosuximide 250 mg per capsule, oral ingestion capsule [N03AD01or]

F

Fenofibrate 200 mg per capsule, oral ingestion capsule [C10AB05or]
Ferrous sulfate 125 mg/5 ml, in 120 ml, oral ingestion liquid [B03AA07or]
Ferrous sulfate 60 mg per tablet, oral ingestion tablet [B03AA07or]
Ferrous sulfate 60 mg + folic acid (vit B9) 0.4 mg per tablet, oral ingestion tablet [B03AD03or]
Flumazenil 0.1 mg/ml, in 10 ml, injection solution [V03AB25inj]
Fluorouracil 5% topical ointment [L01BC02]
Fluoxetine 20 mg per capsule, oral ingestion capsule [N06AB03or]
Fluphenazine (oily) 1 mg/ml, in 1 ml ampoule, injection solution [N05AB02inj]
Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [A11HA11or]
Folic acid (vit B9) 1 mg per tablet, oral ingestion tablet [B03BB01or]
Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [A11HA11or]
Folic acid (vit B9) 5 mg per tablet, oral ingestion tablet [B03BB01or]
Fosamprenavir 700 mg + ritonavir 100 mg (FPV/r) per tablet, oral ingestion tablet [J05AR13or]
Furazolidone 100 mg per tablet, oral ingestion tablet [G01AX06or]
Furazolidone 125 mg/5 ml, in 60 ml, oral syrup [G01AX06or]
Furosemide 10 mg/ml, in 2 ml ampoule, injection solution [C03CA01inj]
Furosemide 20 mg per tablet, oral ingestion tablet [C03CA01or]
Furosemide 40 mg per tablet, oral ingestion tablet [C03CA01or]

G

Gentamicin 0.3% in 5 ml bottle, ophthalmic drop [S01AA11]
Gentamicin 10 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]
Gentamicin 20 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]
Gentamicin 40 mg/ml, in 2 ml ampoule, injection solution [J01GB03inj]
Glibenclamide 5 mg per tablet, oral ingestion tablet [A10BB01or]
Glucose 10% in 1,000 ml bottle, injection solution [B05CX01inj]
Glucose 10% in 500 ml bottle, injection solution [B05CX01inj]
Glucose 4% + sodium chloride 0.18% in 1,000 ml bottle, injection solution [B05BB02inj]
Glucose 4% + sodium chloride 0.18% in 500 ml bottle, injection solution [B05BB02inj]
Glucose 5% in 1,000 ml bottle, injection solution [B05CX01inj]
Glucose 5% in 500 ml bottle, injection solution [B05CX01inj]
Glucose 5% + sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB02inj]
Glucose 5% + sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB02inj]
Glucose 50% injection solution [B05BA03inj]
Glucose 7.5% + lidocaine 5% (lidocaine spinal) injection solution [N01BB52inj]
Glyceril trinitrate (nitroglycerine) 0.5 mg per tablet, sublingual-oral tablet [C01DA02or]
Griseofulvin 125 mg per tablet, oral ingestion tablet [D01BA01or]
Griseofulvin 250 mg per tablet, oral ingestion tablet [D01BA01or]
Griseofulvin 500 mg per tablet, oral ingestion tablet [D01BA01or]

H

Haloperidol 2 mg per tablet, oral ingestion tablet [N05AD01or]
Haloperidol 5 mg/ml, in 1 ml, injection solution [N05AD01inj]
Haloperidol 5 mg per tablet, oral ingestion tablet [N05AD01or]
Halothane 250ml per bottle, inhalation solution [N01AB01inj]
Heparin 1,000 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]

Heparin 2,500 IU/ml, in 5 ml ampoule, injection solution [B01AB01inj]
 Heparin 5,000 IU/ml, in 1 ml ampoule, injection solution [B01AB01inj]
 Hepatitis B monovalent vaccine single dose (HepB) per milliliter per vial, injection solution [J07BC01inj]
 Hydralazine 20 mg/ml, in 2 ml, injection solution [C02DB01inj]
 Hydralazine 25 mg per tablet, oral ingestion tablet [C02DB02or]
 Hydralazine 50 mg per tablet, oral ingestion tablet [C02DB02or]
 Hydrochlorothiazide 25 mg per tablet, oral ingestion tablet [C03AA03or]
 Hydrochlorothiazide 50 mg per tablet, oral ingestion tablet [C03AA03or]
 Hydrocortisone acetate 1% in 15 g tube, topical cream [D07AA02]
 Hydrocortisone sodium succinate 100 mg per vial, injection vial [H02AB09inj]
 Hydrogen peroxide 6% topical solution [D08AX01]
 Hydroxocobalamine (vit B12) 0.5 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]
 Hydroxocobalamine (vit B12) 1 mg/ml, in 1 ml ampoule, injection solution [B03BA03inj]
 Hyoscine (butylbromide, hydrobromide) 10 mg per tablet, oral ingestion tablet [A03BB01or]
 Hyoscine (butylbromide, hydrobromide) 20 mg/ml, in 1 ml ampoule, injection solution [A03BB01inj]

I

Ibuprofen 200 mg per tablet, oral ingestion tablet [M01AE01or]
 Ibuprofen 400 mg per tablet, oral ingestion tablet [M01AE01or]
 Imipramine 10 mg per tablet, oral ingestion tablet [N06AA02or]
 Imipramine 25 mg per tablet, oral ingestion tablet [N06AA02or]
 Indinavir (IDV) 200 mg per capsule, oral ingestion capsule [J05AE02or] → **See: National HIV/AIDS Program List**
 Indinavir (IDV) 333 mg per capsule, oral ingestion capsule [J05AE02or] → **See: National HIV/AIDS Program List**
 Indinavir (IDV) 400 mg per capsule, oral ingestion capsule [J05AE02or] → **See: National HIV/AIDS Program List**
 Indinavir 800 mg + ritonavir 100 mg (IDV/r) per tablet, oral ingestion tablet [J05AR11] → **See: National HIV/AIDS Program List**
 Insulin isophane (NPH) intermediate 100 IU/ml, in 10 ml vial, injection vial [A10AC03inj]
 Insulin isophane (NPH) intermediate 40 IU/ml, in 10 ml vial, injection vial [A10AC03inj]
 Insulin soluble fast 100 IU/ml, in 10 ml vial, injection vial [A10AB01inj]
 Insulin soluble fast 40 IU/ml, in 10 ml vial, injection vial [A10AB01inj]
 Intrauterine device with copper 1 pce per piece, vaginal intrauterine device [G02BA02] → **See: National Family Planning Program List**
 Iodine 200 mg per capsule, oral ingestion capsule [H03CA20or]
 Iodine 480 mg/ml, in 0.5 ml ampoule, oral ampoule [H03CA20or]
 Iodine 540 mg/ml, in 0.57 ml bottle, oral solution [H03CA20or]
 Iron dextran 50 mg/ml, in 2 ml ampoule, injection solution [B03AC06inj]
 Isoflurane in 250 ml, gas [N01AB06]
 Isoniazid (INH) 100 mg per tablet, oral ingestion tablet [J04AC01or] → **See: National Tuberculosis Program List**
 Isoniazid (INH) 300 mg per tablet, oral ingestion tablet [J04AC01or] → **See: National Tuberculosis Program List**
 Isoniazid (INH) 50 mg per tablet, oral ingestion tablet [J04AC01or] → **See: National Tuberculosis Program List**
 Isosorbide dinitrate 10 mg per tablet, sublingual-oral tablet [C01DA08or]
 Isosorbide dinitrate 20 mg per tablet, sublingual-oral tablet [C01DA08or]
 Isosorbide dinitrate 5 mg per tablet, sublingual-oral tablet [C01DA08or]

K

Ketamine 50 mg/ml, in 10 ml vial, injection solution [N01AX03inj]
 Ketoconazole 2% in 15 g tube, topical cream [D01AC08]
 Ketoconazole 2% in 60 ml, topical shampoo [D01AC08]
 Ketoconazole 200 mg per tablet, oral ingestion tablet [J02AB02or]

L

Lactulose 3.33 g/5 ml, in 150 ml bottle, oral ingestion syrup [A06AD11or]
 Lamivudine (3TC) 100 mg per tablet, oral ingestion tablet [J05AF05or] → **See: National HIV/AIDS Program List**
 Lamivudine (3TC) 150 mg per tablet, oral ingestion tablet [J05AF05or] → **See: National HIV/AIDS Program List**
 Lamivudine (3TC) 300 mg per tablet, oral ingestion tablet [J05AF05or] → **See: National HIV/AIDS Program List**
 Lamivudine (3TC) 50 mg/5 ml, oral ingestion suspension [J05AF05or] → **See: National HIV/AIDS Program List**
 Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP) per tablet, oral ingestion tablet [J05AR05or] → **See: National HIV/AIDS Program List**
 Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet [J05AR01or] → **See: National HIV/AIDS Program List**
 Lamivudine 40 mg + stavudine 10 mg (d4T/3TC)/5 ml, oral solution [J05AR09or]
 Levothyroxine 0.05 mg per tablet, oral ingestion tablet [H03AA01or]
 Levothyroxine 0.1 mg per tablet, oral ingestion tablet [H03AA01or]
 Levonorgestrel 0.03 mg per tablet, oral ingestion tablet [G03AC03or]
 Lidocaine 1% in 2 ml, injection vial [N01BB02inj]
 Lidocaine 2% in 15 g tube, topical gel [D04AB04]
 Lidocaine 2% in 2 ml ampoule, injection solution [N01BB02inj]
 Lidocaine 20 mg/ml, in 5 ml ampoule, injection solution [C01BB01inj]
 Lidocaine 4% topical gel [N01BB02]
 Lindane 1% topical shampoo [P03AB02]
 Lopinavir 133.3 mg + ritonavir 33.3 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or] → **See: National HIV/AIDS Program List**
 Lopinavir 200 mg + ritonavir 50 mg (LPV/r) per capsule, oral ingestion capsule [J05AR10or]
 Lopinavir 400 mg + ritonavir 100 mg (LPV/r) per 5 ml, oral ingestion liquid [J05AR10or] → **See: National HIV/AIDS Program List**

M

Magnesium sulfate 500 mg/ml, in 10 ml ampoule, injection solution [N03AX31inj]
 Magnesium sulfate 500 mg/ml, in 20 ml ampoule, injection solution [N03AX31inj]
 Magnesium sulfate 500 mg/ml, in 2 ml ampoule, injection solution [N03AX31inj]
 Mannitol 10% in 100 ml bottle, infusion solution [B05BC01inj]
 Mannitol 20% in 100 ml bottle, infusion solution [B05BC01inj]
 Maraviroc 150 mg per tablet, oral ingestion tablet [J05AX09or] → **See: National HIV/AIDS Program List**
 Maraviroc 300 mg per tablet, oral ingestion tablet [J05AX09or] → **See: National HIV/AIDS Program List**
 Measles diluent 10 doses per vial, injection vial [J07BD01inj]
 Measles vaccine 10 doses per vial, injection vial [J07BD01inj]
 Mebendazole 100 mg per tablet, oral chewable tablet [P02CA01or]
 Medroxyprogesterone acetate depot 150 mg/ml, in 1 ml vial, injection solution [G03AC06inj] → **See: National Family Planning Program List**

Meglumine antimoniate 30% in 5 ml ampoule, injection solution [P01CB01inj] → **See: National Malaria and Leishmania Program List**

Metformin 500 mg per tablet, oral ingestion tablet [A10BA02or]

Methadone 10 mg/ml, in 1 ml ampoule, injection solution [N07BC02inj] → **See: National Drug Dependency Reduction Program**

Methadone 10 mg/ml, oral solution [N07BC02or] → **See: National Drug Dependency Reduction Program**

Methadone 10 mg per tablet, oral ingestion tablet [N07BC02or] → **See: National Drug Dependency Reduction Program**

Methadone 5 mg/ml, oral solution [N07BC02or] → **See: National Drug Dependency Reduction Program**

Methadone 5 mg per tablet, oral ingestion tablet [N07BC02or] → **See: National Drug Dependency Reduction Program**

Methotrexate 2.5 mg per tablet, oral ingestion tablet [M01CX01or]

Methyl dopa 250 mg per tablet, oral ingestion tablet [C02AB01or]

Methylene blue (methylthioninium) 10 mg/ml, in 10 ml ampoule, injection solution [V03AB17inj]

Methylergometrine maleate 0.2 mg/ml, in 1 ml, injection ampoule [G02AB01inj]

Methylrosaniline (gentian violet) 0.5% in 10 ml bottle, topical solution [D01AE02]

Methylrosaniline (gentian violet) 1% in 10 ml bottle, topical solution [D01AE02]

Methylrosaniline (gentian violet) 25 g per bottle, topical crystals [D01AE02]

Metoclopramide 10 mg per tablet, oral ingestion tablet [A03FA01or]

Metoclopramide 5 mg/ml, in 2 ml, injection solution [A03FA01inj]

Metoprolol 1 mg/ml, in 5 ml ampoule, injection solution [C07AB02inj]

Metoprolol 50 mg per tablet, oral ingestion tablet [C07AB02or]

Metronidazole 0.75% in 15 g tube, topical ointment [D06BX01]

Metronidazole 200 mg/5 ml, in 60 ml bottle, oral ingestion suspension [P01AB01or]

Metronidazole 200 mg per tablet, oral ingestion tablet [P01AB01or]

Metronidazole 250 mg per tablet, oral ingestion tablet [P01AB01or]

Metronidazole 400 mg per tablet, oral ingestion tablet [P01AB01or]

Metronidazole 500 mg per tablet, oral ingestion tablet [P01AB01or]

Metronidazole 5 mg/ml, in 100 ml bottle, infusion solution [J01XD01inj]

Midazolam 1 mg/ml, in 1 ml ampoule, injection solution [N05CD08inj]

Misoprostol 200 mcg per tablet, oral ingestion tablet [G02AD20or]

Misoprostol 25 mcg per tablet, vaginal tablet [G02AD06vg]

Morphine (sulfate, hydrochloride) 10 mg/ml, in 1 ml ampoule, injection solution [N02AA01inj]

Moxifloxacin 400 mg per tablet, oral ingestion tablet [J01MA14or] → **See: National Tuberculosis Program List**

Multivitamins and other minerals, including combinations [A11AA03]

Multiple micronutrient formulation per sachet (1 g sachet), oral ingestion powder [A11AA03or]

Multiple micronutrient formulation per tablet, 500 mg tablet, oral ingestion tablet [A11AA03or]

Multivitamins and trace elements [A11AA04]

Multivitamins, other combinations [A11AB00]

Mupirocin 2% in 10 g tube, topical cream [D06AX09]

N

Nalidixic acid 250 mg/5 ml, in 60 ml bottle, oral ingestion suspension [J01MB02or]

Nalidixic acid 250 mg per tablet, oral ingestion tablet [J01MB02or]

Nalidixic acid 500 mg per tablet, oral ingestion tablet [J01MB02or]

Naloxone 400 mcg/ml, in 1 ml, injection solution [V03AB15inj]

Naphazoline 0.05% in 10 ml bottle, nasal drop [R01AA08]

Nelfinavir (NFV) 200 mg/5 ml, oral ingestion suspension [J05AE04or] → **See: National HIV/AIDS Program List**

Nelfinavir (NFV) 250 mg per tablet, oral ingestion tablet [J05AE04or] → **See: National HIV/AIDS Program List**

Nelfinavir (NFV) 50 mg/g in 144 g pack, oral ingestion powder [J05AE04or] → **See: National HIV/AIDS Program List**

Nelfinavir (NFV) 625 mg per tablet, oral ingestion tablet [J05AE04or] → **See: National HIV/AIDS Program List**

Neomycin sulfate 0.5% in 15 g tube, topical cream [S01AA03]

Neostigmine bromide 15 mg per tablet, oral ingestion tablet [N07AA01or]

Neostigmine methylsulfate 0.5 mg/ml, in 10 ml, injection solution [N07AA01inj]

Niclosamide 500 mg per tablet, oral ingestion chewable tablet [P02DA01or]

Nifedipine 10 mg per tablet, oral ingestion tablet [G02CA04or]

Nifedipine 20 mg per capsule, oral ingestion capsule [G02CA04or]

Nifedipine slow-release 10 mg per tablet, oral ingestion tablet [C08CA05or]

Nifedipine slow-release 20 mg per tablet, oral ingestion tablet [C08CA05or]

Nitrofurantoin 100 mg per tablet, oral ingestion tablet [J01XE01or]

Norethisterone 5 mg per tablet, oral ingestion tablet [G03DC02or]

Norgestrel 0.075 mg per tablet, oral ingestion tablet [G03AC10or] → **See: National Family Planning Program List**

Nortriptyline 10 mg per tablet, oral ingestion tablet [N06AA10or]

Nystatin 100,000 IU/g, in 15 g tube, vaginal cream [G01AA01vg]

Nystatin 100,000 IU/g, in 25 g tube, topical cream [D01AA01]

Nystatin 100,000 IU/ml, in 15 ml, oral topical drop [A07AA02or]

Nystatin 100,000 IU per ovule, vaginal suppository [G01AA01vg]

Nystatin 100,000 IU per tablet, oral ingestion tablet [A07AA02or]

Nystatin 100,000 IU per tablet, vaginal tablet [G01AA01vg]

Nystatin 500,000 IU per tablet, oral ingestion tablet [A07AA02or]

O

Omeprazole 20 mg per capsule, oral ingestion capsule [A02BC01or]

Omeprazole 40 mg per capsule, oral ingestion capsule [A02BC01or]

Omeprazole 40 mg per vial, injection vial [A02BC01or]

Opium tincture 10% oral solution [N07BC59or] → **See: National Drug Dependency Reduction Program**

Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine [J07BF01or]

Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine [J07BF01or]

Oral polio vaccine–trivalent (OPV-T) 20 doses per vial, oral vaccine [J07BF02or]

Oral rehydration salts (ORS) 20.5 g/L, in 1 L sachet, oral powder [A07CA01or]

Oral rehydration salts (ORS) 27.9 g/L, in 1 L sachet, oral powder [A07CA01or]

Oral rehydration salts (ORS ReSoMal) in 1 L sachet, oral ingestion powder [A07CA01or]

Oxygen inhalation gas [V03AN01]

Oxytocin 10 IU/ml, in 1 ml ampoule, injection solution [H01BB02inj]

P

Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules [J04AA01or] → **See: National Tuberculosis Program List**

Paracetamol (acetaminophen) 100 mg/ml, in 15 ml bottle, oral ingestion drop [N02BE01or]

Paracetamol (acetaminophen) 100 mg per tablet, oral ingestion tablet [N02BE01or]

Paracetamol (acetaminophen) 120 mg/5 ml, in 60 ml bottle, oral syrup [N02BE01or]

Paracetamol (acetaminophen) 125 mg per suppository, rectal suppository [N02BE01rec]

Paracetamol (acetaminophen) 325 mg per tablet, oral ingestion tablet [N02BE01or]

Paracetamol (acetaminophen) 500 mg per tablet, oral ingestion tablet [N02BE01or]

Penicillamine 125 mg per tablet, oral ingestion tablet [M01CC01or]

Penicillamine 250 mg per tablet, oral ingestion tablet [M01CC01or]

Penicillin benzyl (peni G crystal) 1 MU per vial, injection vial [J01CE01inj]

Penicillin benzyl (peni G crystal) 5 MU per vial, injection vial [J01CE01inj]

Penicillin benzyl 0.5 MU + penicillin procaine 1.5 MU per vial, injection vial [J01CE09inj]

Penicillin benzyl 1 MU + penicillin procaine 3 MU per vial, injection vial [J01CE09inj]

Penicillin benzyl 2 MU + penicillin procaine 6 MU per vial, injection vial [J01CE09inj]

Penicillin benzyl benzathine 1.2 MU per vial, injection vial [J01CE08inj]

Penicillin benzyl benzathine 2.4 MU per vial, injection vial [J01CE08inj]

Penicillin benzyl procaine 2 MU per vial, injection vial [J01CE09inj]

Penicillin benzyl procaine 4 MU per vial, injection vial [J01CE09inj]

Penicillin V (phenoxymethylpenicillin) 250 mg/5 ml, in 100 ml bottle, oral ingestion suspension [J01CE02or]

Penicillin V (phenoxymethylpenicillin) 250 mg per tablet, oral ingestion tablet [J01CE02or]

Penicillin V (phenoxymethylpenicillin) 500 mg per tablet, oral ingestion tablet [J01CE02or]

Peritoneal dialytics, isotonic solutions 1,000 ml per bag, parenteral solution [B05DA00]

Permethrin 1% in 60 ml bottle, topical lotion [P03AC04]

Permethrin 5% in 30 g tube, topical cream [P03AC04]

Pethidine 100 mg per tablet, oral ingestion tablet [N02AB02or]

Pethidine 50 mg/ml, injection solution [N02AB02inj]

Pethidine 50 mg per tablet, oral ingestion tablet [N02AB02or]

Phenobarbital 100 mg/ml, in 2 ml, injection solution [N03AA02inj]

Phenobarbital 100 mg per tablet, oral ingestion tablet [N03AA02or]

Phenobarbital 15 mg per tablet, oral ingestion tablet [N03AA02or]

Phenobarbital 25 mg per tablet, oral ingestion tablet [N03AA02or]

Phenobarbital 30 mg per tablet, oral ingestion tablet [N03AA02or]

Phenobarbital 50 mg/ml, in 2 ml, injection solution [N03AA02inj]

Phenobarbital 50 mg per tablet, oral ingestion tablet [N03AA02or]

Phytomenadione (vit K) 10 mg/ml, in 1 ml, injection solution [B02BA01inj]

Phytomenadione (vit K) 10 mg per tablet, oral ingestion tablet [B02BA01or]

Pilocarpine 2% in 15 ml bottle, ophthalmic drop [S01EB01]

Pilocarpine 4% in 15 ml bottle, ophthalmic drop [S01EB01]

Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial [J07AL02inj]

Pneumococcal conjugated vaccine 7-valent single dose per vial, injection vial [J07AL02inj]

Potassium chloride 11.2% in 20 ml ampoule, injection solution [B05XA01inj]

Potassium chloride 15% in 20 ml ampoule, injection solution [B05XA01inj]

Potassium chloride 7.5% in 20 ml ampoule, injection solution [B05XA01inj]

Potassium iodide 60 mg per tablet, oral ingestion tablet [V03AB21or]

Potassium permanganate 0.01% topical solution [D08AX06]

Povidone iodine 10% topical solution [D08AG02]

Pralidoxime 500 mg/ml, injection solution [V03AB04inj]

Prednisolone 0.5% in 5 ml bottle, ophthalmic drop [S01BA04]

Prednisolone 1% in 5 ml bottle, ophthalmic drop [S01BA04]

Prednisolone 5 mg per tablet, oral ingestion tablet [H02AB06or]

Primaquine 15 mg per tablet, oral ingestion tablet [P01BA03or] → **See: National Malaria and Leishmania Control Program List**

Primaquine 7.5 mg per tablet, oral ingestion tablet [P01BA03or] → **See: National Malaria and Leishmania Control Program List**

- Procainamide 100 mg/ml, in 10 ml ampoule, injection solution [C01BA02inj]
- Procainamide 250 mg per tablet, oral ingestion tablet [C01BA02or]
- Promethazine 25 mg/ml, in 2 ml ampoule, injection solution [R06AD02inj]
- Promethazine 25 mg per tablet, oral ingestion tablet [R06AD02or]
- Promethazine 5 mg/5 ml, oral syrup [R06AD02or]
- Propofol 10 mg/ml, in 100 ml ampoule, infusion solution [N01AX10inj]
- Propofol 10 mg/ml, in 20 ml, infusion solution [N01AX10inj]
- Propranolol 10 mg per tablet, oral ingestion tablet [C07AA05or]
- Propranolol 20 mg per tablet, oral ingestion capsule or tablet [C07AA05or]
- Propranolol 40 mg per tablet, oral ingestion tablet [C07AA05or]
- Protamine sulfate 10 mg/ml, in 5 ml ampoule, injection solution [V03AB14inj]
- Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet [J04AK01or] → **See: National Tuberculosis Program List**
- Pyrazinamide (PZA) 400 mg per tablet, oral ingestion tablet [J04AK01or] → **See: National Tuberculosis Program List**
- Pyrazinamide (PZA) 500 mg per tablet, oral ingestion tablet [J04AK01or] → **See: National Tuberculosis Program List**
- Pyridoxine (vit B6) 25 mg per tablet, oral ingestion tablet [A11HA02or]
- Pyridoxine (vit B6) 40 mg per tablet, oral ingestion tablet [A11HA02or]

Q

- Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution [P01BC01inj] → **See: National Malaria and Leishmania Control Program List**
- Quinine sulfate 300 mg per tablet, oral ingestion tablet [P01BC01or] → **See: National Malaria and Leishmania Control Program List**

R

- Rabies antitoxin 150 mg/ml, in 1 ml, injection vial [J06AA06inj]
- Raltegravir 400 mg per tablet, oral ingestion tablet [J05AX08or] → **See: National HIV/AIDS Program List**
- Ranitidine 150 mg per tablet, oral ingestion tablet [A02BA02or]
- Ranitidine 25 mg/ml, in 2 ml ampoule, injection solution [A02BA02inj]
- Ranitidine 300 mg per tablet, oral ingestion tablet [A02BA02or]
- Retinol (oily) (vit A) 100,000 IU/ml, oral solution [A11CA01or]
- Retinol (vit A) 100,000 IU per ampoule, injection solution [A11CA01inj]
- Retinol (vit A) 100,000 IU per tablet, oral ingestion tablet [A11CA01or]
- Retinol (vit A) 200,000 IU per tablet, oral ingestion tablet [A11CA01or]
- Retinol (vit A) 850 IU + colecalciferol (vit D3) 85 IU/g, in 30 g tube, topical ointment [D02AX00]
- Rifampicin 150 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]
- Rifampicin 300 mg per tablet or capsule, oral ingestion tablet or capsule [J04AB02or]
- Rifampicin 150 mg + isoniazid 75 mg (RH) per tablet, oral ingestion tablet [J04AM02or] → **See: National Tuberculosis Program List**
- Rifampicin 150 mg + isoniazid 75 mg + ethambutol 275 mg (RHE) per tablet, oral ingestion tablet [J04AM07or] → **See: National Tuberculosis Program List**
- Rifampicin 300 mg + dapsone 50 mg + clofazimine 50 mg per tablet, oral ingestion tablet [J04BA01or] → **See: National Leprosy Program List**
- Rifampicin 60 mg + isoniazid 30 mg (RH) per tablet, oral ingestion tablet [J04AM02or] → **See: National Tuberculosis Program List**
- Rifampicin 60 mg + isoniazid 30 mg + pyrazinamide 150 mg (RHZ) per tablet, oral ingestion tablet [J04AM05or] → **See: National Tuberculosis Program List**

Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg (RHZE) per tablet or capsule, oral ingestion tablet or capsule [J04AM06or] → **See: National Tuberculosis Program List**

Ringer's lactate in 1,000 ml, infusion solution [B05BB02inj]

Ringer's lactate in 500 ml, infusion solution [B05BB02inj]

Ritonavir (RTV) 100 mg per tablet, oral ingestion tablet [J05AE03or] → **See: National HIV/AIDS Program List**

Ritonavir (RTV) 400 mg/5 ml, oral ingestion liquid [J05AE03or] → **See: National HIV/AIDS Program List**

Rotavirus monovalent/pentavalent single or double dose in 2 vials, oral vaccine [J07BH01or]

Rubella vaccine, live attenuated in single dose, injection vial [J07BJ01inj]

S

Salbutamol 0.05 mg/ml, in 5 ml ampoule, injection solution [R03CC02inj]

Salbutamol 0.5 mg/ml, in 1 ml ampoule, injection solution or vial [R03CC02inj]

Salbutamol 0.1 mg per dose, in 200 dose bottle, inhalation solution [R03AC02ihas]

Salbutamol 2 mg/5 ml, in 60 ml bottle, oral syrup [R03CC02or]

Salbutamol 2 mg per tablet, oral ingestion tablet [R03CC02or]

Salbutamol 4 mg per tablet, oral ingestion tablet [R03CC02or]

Salbutamol 5 mg/ml, nebulizer solution [R03AC02ihsl]

Salicylic acid 5% topical solution [D01AE12]

Saquinavir (SQV) 200 mg per capsule, oral ingestion capsule [J05AE01or] → **See: National HIV/AIDS Program List**

Saquinavir 200 mg + ritonavir 500 mg (SQV/r) per tablet, oral ingestion tablet [J05AR08or]

Scorpion antivenom in 5 ml, injection vial [J06AA20inj]

Silver sulfadiazine 1% in 500 g container, topical cream [D06BA01]

Silver sulfadiazine 1% in 20g tube, topical cream [D06BA01]

Sodium bicarbonate 1.4% in 20 ml vial, injection vial [B05CB04inj]

Sodium bicarbonate 8.4% in 10 ml vial, injection vial [B05CB04inj]

Sodium chloride 0.65% in 10 ml, nasal drop [R01AX30]

Sodium chloride 0.9% in 1,000 ml bottle, injection solution [B05BB01inj]

Sodium chloride 0.9% in 500 ml bottle, injection solution [B05BB01inj]

Sodium hypochlorite (chlorine) 0.5% topical solution [D08AX07]

Sodium stibogluconate 100 mg/ml, injection solution [P01CB02inj] → **See: National Malaria and Leishmania Control Program List**

Spirolactone 25 mg per tablet, oral ingestion tablet [C03DA01or]

Spirolactone 50mg per tablet, oral ingestion tablet [C03DA01or]

Stavudine 30 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]

Stavudine 40 mg + lamivudine 150 mg (d4T/3TC) per tablet, oral ingestion tablet [J05AR09or]

Streptomycin (STM) 1 g per vial, injection vial [J04AB31inj] → **See: National Tuberculosis Program List**

Streptomycin 1 g per vial, injection vial [J01GA01inj]

Sulfacetamide 10% in 15 ml bottle, ophthalmic drop [S01AB04]

Sulfacetamide 20% in 15 ml bottle, ophthalmic drop [S01AB04]

Sulfamethoxazole 100 mg + trimethoprim 20 mg (co-trimoxazole) per tablet, oral ingestion tablet [J01EE01or]

Sulfamethoxazole 200 mg + trimethoprim 40 mg (co-trimoxazole)/5 ml, in 50 ml bottle, oral ingestion suspension [J01EE01or]

Sulfamethoxazole 400 mg + trimethoprim 80 mg per tablet (co-trimoxazole), oral ingestion tablet [J01EE01or]

Sulfasalazine 500 mg per tablet, oral ingestion tablet [M01CX02or]

Sulfur 2% + salicylic acid 1% topical ointment [D10AB02]

Suxamethonium 50 mg/ml, in 2 ml ampoule, injection solution [M03AB01inj]

T

Terbinafine 1% in 30 g tube, topical cream [D01AE15]
 Terbinafine 125 mg per tablet, oral ingestion tablet [D01BA02or]
 Terbinafine 250 mg per tablet, oral ingestion tablet [D01BA02or]
 Tetanus toxoid vaccine 20 dosed per vial, injection vial [J07AM01inj]
 Tetracaine 0.5% in 15 ml bottle, ophthalmic drop [S01HA03]
 Tetracycline 1% in 5 g, ophthalmic ointment [S01AA09]
 Thiopental sodium 1 g per vial, injection powder [N01AF03inj]
 Thiopental sodium 500 mg per vial, injection powder [N01AF03inj]
 Timolol 0.25% in 5 ml bottle, ophthalmic drop [S01ED01]
 Timolol 0.5% in 5 ml bottle, ophthalmic drop [S01ED01]
 Tramadol 100 mg per capsule or tablet, oral ingestion capsule or tablet [N02AX02or]
 Tramadol 50 mg/ml, in 2 ml, injection solution [N02AX02inj]
 Trihexyphenidyl 2 mg per tablet, oral ingestion tablet [N04AA01or]
 Tropicamide 0.5% in 15 ml bottle, ophthalmic drop [S01FA06]
 Tropicamide 1% in 3 ml bottle, ophthalmic drop [S01FA06]
 Tuberculin purified protein derivative 100 IU/ml, injection solvent [V04CF01]
 Tuberculin purified protein derivative 10 IU/ml, injection solvent [V04CF01]
 Tuberculosis vaccine (BCG) with diluent 20 doses per vial, injection vial [J07AN01inj]

V

Valproic acid (sodium valproate) 200 mg per tablet, oral ingestion tablet [N03AG01or]
 Valproic acid (sodium valproate) 500 mg per tablet, oral ingestion tablet [N03AG01or]
 Vaseline [V99AB00]
 Verapamil 2.5 mg/ml, in 2 ml ampoule, injection solution [C08DA01inj]
 Verapamil 40 mg per tablet, oral ingestion tablet [C08DA01or]
 Verapamil 80 mg per tablet, oral ingestion tablet [C08DA01or]
 Vit A 400 mcg + vit C 30 mg + vit D 5 mcg + vit E 5 mg + vit B1 0.5 mg + riboflavin 0.5 mg + niacin (vit B3) 6 mg + pyridoxine (vit B6) 0.5 mg + cyanocobalamine (vit B12) 0.9 mcg + folic acid (vit B9) 150 mcg + iron 10 mg + zinc 4.1 mg + copper 0.56 mg + selenium 17 mcg + iodine (multiple micronutrient) per sachet [A11AA03or]
 Vit A 400 mcg + vit C 30 mg + vit D 5 mcg + vit E 5 mg + vit B1 0.5 mg + riboflavin 0.5 mg + niacin (vit B3) 6 mg + pyridoxine (vit B6) 0.5 mg + cyanocobalamine (vit B12) 0.9 mcg + folic acid (vit B9) 150 mcg + iron 10 mg + zinc 4.1 mg + copper 0.56 mg + selenium 17 mcg + iodine 90 mcg (multiple micronutrient) per tablet [A11AA03or]

W

Water for injection, in 10 ml ampoule, injection solution [V07AB01inj]
 Water for Injection, in 5 ml ampoule, injection solution [V07AB01inj]

Z

Zidovudine (AZT) 100 mg per capsule, oral ingestion capsule [J05AF01or] → **See: National HIV/AIDS Program List**
 Zidovudine (AZT) 10 mg/ml, in 20 ml vial, injection solution [J05AF01inj] → **See: National HIV/AIDS Program List**
 Zidovudine (AZT) 250 mg per capsule or tablet, oral ingestion capsule or tablet [J05AF01or] → **See: National HIV/AIDS Program List**
 Zidovudine (AZT) 300 mg per tablet, oral ingestion tablet [J05AF01or] → **See: National HIV/AIDS Program List**

Zidovudine (AZT) 50 mg/5 ml, oral ingestion suspension [J05AF01or] → **See: National HIV/AIDS**

Program List

Zinc oxide 10% in 20 g tube, topical ointment [D02AB01]

Zinc oxide 20% in 20 g tube, topical cream [D02AB01]

Zinc sulfate 10 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]

Zinc sulfate 20 mg per tablet, oral ingestion tablet, blister pack of 10 [A12CB01or]

Special Programs List

National Family Planning Program List

Items on the National Family Planning Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

Condom with and without nonoxinol 1 pce per piece, topical
Ethinylestradiol 0.035 mg + norethisterone 1 mg per tablet, oral ingestion tablet
Ethinylestradiol 0.03 mg + norgestrel 0.3 mg per tablet, oral ingestion tablet
Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg per tablet, oral ingestion tablet
Intrauterine device with copper 1 pce per piece, vaginal intrauterine device
Medroxyprogesterone acetate depot 150 mg/ml, in 1 ml vial, injection solution
Levonorgestrel 0.03mg per tablet, oral ingestion tablet
Norgestrel 0.075 mg per tablet, oral ingestion tablet

National Postpartum Hemorrhage Program List

Items on the National Postpartum Hemorrhage Program List can be imported and used only with explicit written approval and under supervision of the MoPH National Postpartum Hemorrhage Program, under Reproductive Health Directorate. The items included in this list are not for general or commercial use in the private sector.

Misoprostol 200 mcg per tablet, oral ingestion tablet
Misoprostol 25 mcg per tablet, vaginal tablet

National HIV/AIDS Program List and National Drug Demand Reduction List

Items on the National HIV/AIDS Program list can be imported and used by the private and public sector. They should only be dispensed on prescription. Items on the drug demand reduction program can be imported, manufactured and used as per Narcotics Medicines Laws, recommendations of Drug Demand Reduction Committee (DDRC), International Narcotics Control Board (INCB) and BPHS/EPHS specifications. These medicines are not for public use by private sector.

HIV/AIDS Medicines

Abacavir (ABC) 300 mg per tablet, oral ingestion tablet
 Atazanavir 300 mg + ritonavir 100 mg (ATV/RTV) per tablet, oral ingestion tablet
 Efavirenz (EFV) 100 mg per capsule, oral ingestion capsule
 Efavirenz (EFV) 150 mg/5 ml, oral ingestion liquid
 Efavirenz (EFV) 200 mg per capsule, oral ingestion capsule
 Efavirenz (EFV) 50 mg per capsule, oral ingestion capsule
 Efavirenz (EFV) 600 mg per tablet, oral ingestion tablet
 Efavirenz 600 mg + emtricitabine 200 mg + tenofovir 300 mg (EFV/FTC/TDF) per tablet, oral ingestion tablet
 Emtricitabine (FTC) 200 mg per capsule, oral ingestion capsule
 Emtricitabine (FTC) 50 mg/5 ml, oral ingestion liquid
 Emtricitabine 200 mg + tenofovir 300 mg (FTC/TDF) per tablet, oral ingestion tablet
 Enfuvirtide 108 mg per vial, injection powder
 Entecavir 0.5 mg per tablet, oral ingestion tablet
 Etravirine 25 mg per tablet, oral ingestion tablet
 Indinavir (IDV) 200 mg per capsule, oral ingestion capsule
 Indinavir (IDV) 333 mg per capsule, oral ingestion capsule
 Indinavir (IDV) 400 mg per capsule, oral ingestion capsule
 Indinavir 800 mg + ritonavir 100 mg (IDV/r) per tablet, oral ingestion tablet
 Lamivudine (3TC) 100 mg per tablet, oral ingestion tablet
 Lamivudine (3TC) 150 mg per tablet, oral ingestion tablet
 Lamivudine (3TC) 300 mg per tablet, oral ingestion tablet
 Lamivudine (3TC) 50 mg/5 ml, oral ingestion suspension
 Lamivudine 150 mg + nevirapine 200 mg + zidovudine 300 mg (AZT/3TC/NVP) per tablet, oral ingestion tablet
 Lamivudine 150 mg + zidovudine 300 mg (AZT/3TC) per tablet, oral ingestion tablet
 Lopinavir 133.3 mg + ritonavir 33.3 mg (LPV/r) per capsule, oral ingestion capsule
 Lopinavir 400 mg + ritonavir 100 mg (LPV/r)/5 ml, oral ingestion liquid
 Maraviroc 150 mg per tablet, oral ingestion tablet
 Maraviroc 300 mg per tablet, oral ingestion tablet
 Nelfinavir (NFV) 200 mg/5 ml, oral ingestion suspension
 Nelfinavir (NFV) 250 mg per tablet, oral ingestion tablet
 Nelfinavir (NFV) 50 mg per pack, oral powder
 Nelfinavir (NFV) 625 mg per tablet, oral ingestion tablet
 Nevirapine (NVP) 200 mg per tablet, oral ingestion tablet
 Nevirapine (NVP) 50 mg/5 ml, oral ingestion liquid
 Raltegravir 400 mg per tablet, oral ingestion tablet
 Ritonavir (RTV) 100 mg per tablet, oral ingestion tablet
 Ritonavir (RTV) 400 mg/5 ml, oral ingestion liquid
 Saquinavir (SQV) 200 mg per capsule, oral ingestion capsule
 Stavudine 30 mg + lamivudine 150 mg + nevirapine 200 mg (d4T/3TC/NVP) per tablet, oral ingestion tablet
 Tenofovir (TDF) 300 mg per tablet, oral ingestion tablet
 Zidovudine (AZT) 100 mg per capsule, oral ingestion capsule

Zidovudine (AZT) 10 mg/ml, in 20 ml vial, injection solution
Zidovudine (AZT) 250 mg per capsule or tablet, oral ingestion capsule or tablet
Zidovudine (AZT) 300 mg per tablet, oral ingestion tablet
Zidovudine (AZT) 50 mg/5 ml, oral ingestion suspension

National Drug Demand Reduction Medicines

Buprenorphine 2 mg per tablet, oral ingestion tablet
Buprenorphine 8 mg per tablet, oral ingestion tablet
Methadone 10 mg/ml, in 1 ml ampoule, injection solution
Methadone 10 mg/ml, oral solution
Methadone 10 mg per tablet, oral ingestion tablet
Methadone 5 mg/ml, oral solution
Methadone 5 mg per tablet, oral ingestion tablet
Opium tincture 10% oral solution

National Malaria and Leishmania Control Program List

Items on the National Malaria and Leishmania Control Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

Artemether oily 20 mg/ml, injection solution
Artemether oily 40 mg/ml, injection solution
Artemether oily 80 mg/ml, injection solution
Artesunate 100 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet (co-blister), oral ingestion tablet
Artesunate 300 mg + pyrimethamine 50 mg + sulfadoxine 1,000 mg per tablet, oral ingestion tablet
Artesunate 50 mg + pyrimethamine 25 mg + sulfadoxine 500 mg per tablet, oral ingestion tablet
Artesunate 600 mg + pyrimethamine 75 mg + sulfadoxine 1,500 mg per tablet, oral ingestion tablet
Chloroquine (base) 150 mg per tablet, oral ingestion tablet
Chloroquine (base) 50 mg/5 ml, in 60 ml, oral syrup
Meglumine antimoniate 30% in 5 ml ampoule, injection solution
Primaquine 15 mg per tablet, oral ingestion tablet
Primaquine 7.5 mg per tablet, oral ingestion tablet
Quinine dihydrochloride 300 mg/ml, in 2 ml ampoule, injection solution
Quinine sulfate 300 mg per tablet, oral ingestion tablet
Sodium stibogluconate 100 mg/ml, injection solution

National Tuberculosis Program List

Items on the National Tuberculosis Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

Amikacin 500mg per milliliter, in 2ml vial, injection vial
 Capreomycin 1 g per vial, injection powder
 Cycloserine 250 mg per capsule, oral ingestion capsule
 Ethambutol (E) 275 mg + isoniazid 75 mg + pyrazinamide 400 mg + rifampicin 150 mg (RHZ) per tablet, oral tablet
 Ethambutol (EMB) 100 mg per tablet, oral ingestion tablet
 Ethambutol (EMB) 400 mg per tablet, oral ingestion tablet
 Ethambutol (EMB) 400 mg + isoniazid 150 mg per tablet, oral ingestion tablet
 Ethambutol 400 mg + isoniazid 75 mg (EH) per tablet, oral ingestion tablet
 Ethionamide 250 mg per tablet, oral ingestion tablet
 Isoniazid (INH) 100 mg per tablet, oral ingestion tablet
 Isoniazid (INH) 300 mg per tablet, oral ingestion tablet
 Isoniazid (INH) 50 mg per tablet, oral ingestion tablet
 Moxifloxacin 400 mg per tablet, oral ingestion tablet
 Para-aminosalicylic acid (PAS) 4 g per sachet, oral ingestion granules
 Pyrazinamide (PZA) 150 mg per tablet, oral ingestion tablet
 Pyrazinamide (PZA) 400 mg per tablet, oral ingestion tablet
 Pyrazinamide (PZA) 500 mg per tablet, oral ingestion tablet
 Rifampicin 150 mg + isoniazid 75 mg (RH) per tablet, oral ingestion tablet
 Rifampicin 150 mg + isoniazid 75 mg + ethambutol 275 mg (RHE) per tablet, oral ingestion tablet
 Rifampicin 60 mg + isoniazid 30 mg (RH) per tablet, oral ingestion tablet
 Rifampicin 60 mg + isoniazid 30 mg + pyrazinamide 150 mg (RHZ) per tablet, oral ingestion tablet
 Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg (RHZE) per tablet, oral ingestion tablet or capsule
 Streptomycin (STM) 1 g per vial, injection vial

National Leprosy Program List

Items on the National Leprosy Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS or EPHS.

Clofazimine (CLO) 100 mg per capsule, oral ingestion capsule

Clofazimine (CLO) 50 mg per capsule, oral ingestion capsule

Dapsone (DDS) 100 mg per tablet, oral ingestion tablet

Dapsone (DDS) 25 mg per tablet, oral ingestion tablet

Dapsone (DDS) 50 mg per tablet, oral ingestion tablet

Rifampicin 300 mg + dapsone 50 mg + clofazimine 50 mg per tablet, oral ingestion tablet

Rifampicin 600 mg + dapsone 100 mg + clofazimine 50 mg per tablet, oral ingestion tablet

National EPI Program List

From the items on the EPI Program List, six vaccines (BCG, OPV, DPT-HepB-Hib, PCV1, measles, and TT) should be available in the public and private health facilities without charges and its sale in private and public health facilities are not allowed.

Diphtheria, pertussis, tetanus vaccine 20 doses per vial, injection vial
Diphtheria, pertussis, tetanus, HepB, Hib vaccine 20 doses per vial, injection vial
Diphtheria, pertussis, tetanus, Hepatitis B vaccine 10 doses per milliliter, injection vial
Measles vaccine 10 doses per vial, injection vial
Oral polio vaccine–bivalent (OPV-B) 20 doses per vial, oral vaccine
Oral polio vaccine–monovalent (OPV-M) 20 doses per vial, oral vaccine
Oral polio vaccine–trivalent (OPV-T) 20 doses per vial, oral vaccine
Pneumococcal conjugated vaccine 23-valent single dose per vial, injection vial
Pneumococcal conjugated vaccine 7-valent 1dose per vial, injection vial
Rotavirus monovalent/pentavalent single or double dose in 2 vials, oral vaccine
Rubella vaccine, live attenuated in single dose, injection vial
Tetanus toxoid vaccine 20 doses per vial, injection vial
Tuberculosis vaccine (BCG) 20 doses per vial, injection vial

Reference Table for Vitamin and Mineral Supplements

Table 3 lists the limits, as defined by the Food and Nutrition Boards of the Institute of Medicine, US National Academy of Sciences, for supplemental daily intake of vitamins and minerals.

Table 3. Reference Table for Vitamin and Mineral Supplements

Acronym	ATC	Name	Form	Therapeutic Defined Daily Dose (adult)	Supplement Daily Intake		
					Min.	Max.	Unit
Vit A	A11CA01	Retinol	Inj.	50 IU	0.4	1.3	mg
Vit A	A11CA01	Retinol	Oral	50 IU	0.4	1.3	mg
Vit B1 ^a	A11DA01	Thiamine ^a	Inj.	50 mg	0.4	1.4	mg
Vit B1 ^a	A11DA01	Thiamine ^a	Oral	50 mg			
Vit B12 ^a	B03BA04	Cobamamide ^a					
Vit B12 ^a	B03BA01	Cyanocobalamin ^a	Nas.	0.07 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA01	Cyanocobalamin ^a	Oral	1 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA01	Cyanocobalamin ^a	Inj.	0.02 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA02	Cyanocobalamin tannin complex ^a	Inj.	0.02 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA03	Hydroxocobalamin ^a	Inj.	0.02 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA05	Mecobalamin ^a	Oral	1.5 mg	0.4	2.8	mcg
Vit B12 ^a	B03BA05	Mecobalamin ^a	Inj.	0.2 mg	0.4	2.8	mcg
Vit B2 ^a	A11HA04	Riboflavin ^a			0.3	1.6	mg
Vit B3 ^a	A11HA01	Nicotinamide ^a	Oral	150 mg	2	17	mg
Vit B5 ^a	A11HA31	Calcium pantothenate ^a			1.7	7	mg
Vit B5a ^a	A11HA30	Dexpanthenol ^a			1.7	7	mg
Vit B5 ^a	A11HA32	Pantethine ^a			1.7	7	mg
Vit B6 ^a	A11HA06	Pyridoxal phosphate ^a			0.1	2	mg
Vit B6 ^a	A11HA02	Pyridoxine ^a	Oral	160 mg	0.1	2	mg
Vit B6 ^a	A11HA02	Pyridoxine ^a	Inj.	160 mg	0.1	2	mg
Vit B7 ^a	A11HA05	Biotin ^a			5	35	mcg
Vit B8 ^a	A11HA07	Inositol ^a					
Vit B9 ^a	B03BB01	Folic acid ^a (prophylaxis)	Oral	0.4 mg	0.065	0.5	mg
Vit B9 ^a	B03BB01	Folic acid ^a (therapy)	Inj.	10 mg	0.065	0.5	mg
Vit C ^a	A11GA01	Ascorbic acid ^a	Inj.	200 mg	40	120	mg
Vit C ^a	A11GA01	Ascorbic acid ^a	Oral	200 mg	40	120	mg
Vit D	A11CC03	Alfacalcidol	Oral	0.001 mg			
Vit D	A11CC03	Alfacalcidol	Inj.	0.001 mg			
Vit D	A11CC06	Calcifediol			5	15	mcg
Vit D	A11CC04	Calcitriol	Oral	0.001 mg			
Vit D	A11CC04	Calcitriol	Inj.	0.001 mg			
Vit D	A11CC05	Colecalciferol			5	15	mcg
Vit D	A11CC02	Dihydrotachysterol	Oral	1 mg	5	15	mcg
Vit D	A11CC01	Ergocalciferol			5	15	mcg
Vit D	A11CC07	Paricalcitol					
Vit E	A11HA03	Tocopherol	Oral	200 mg	4	19	mg

^a Water soluble vitamins may exceed maximum strengths up to 20%.

Acronym	ATC	Name	Form	Therapeutic Defined Daily Dose (adult)	Supplement Daily Intake		
					Min.	Max.	Unit
Vit E	A11HA03	Tocopherol	Inj.	200 mg	4	19	mg
Vit K3	B02BA02	Menadione	Oral	10 mg	0.02	0.09	mcg
Vit K3	B02BA02	Menadione	Inj.	2 mg	0.02	0.09	mcg
Vit K3	B02BA01	Phytomenadione	Oral	20 mg	0.02	0.09	mcg
Vit K3	B02BA01	Phytomenadione	Inj.	20mg	0.02	0.09	mcg
		Calcium			210	1,000	mg
		Chromium			0.2	45	mcg
		Copper			0.34	13	mg
		Fluoride			0.01	3	mg
		Iodine			0.09	0.29	mg
		Iron			0.27	9	mg
		Magnesium			0.08	0.32	mg
		Manganese			0.003	2.6	mg
		Molybdenume			0.017	0.05	mg
		Phosphor			450	700	mg
		Selenium			0.02	0.07	mg
		Zinc			2	12	mg

Source: National Academy of Sciences. 2002. *Dietary Reference Intakes*. Washington, DC: Food and Nutrition Boards, Institute of Medicine, National Academy of Sciences. www.nap.edu

Annex A. Procedure for Application for Inclusion of Medicines on the Essential Medicines List of the Ministry of Public Health of Afghanistan

General

The EML selection process is based on a well-developed procedure that ensures transparency of the inclusion process.

Applications for inclusion in the EML will be considered only if the application form has been fully completed for each proposed medicine. One application form must be filled out for each proposed medicine. An application for inclusion in the EML can be submitted only for medicines already on the LML list. If the applicant has urgent and compelling reasons for inclusion of a non-LML medicine in the EML, the request for inclusion in both the LML and EML can be submitted and will be processed at the same time. The following conditions must be met before an application for inclusion in the EML will be considered:

- The applicant's contact details are complete.
- The medicine's INN—including strength, route of administration, and presentation—has been provided.
- The indications have been clearly stated.
- The details of the proposed regimen for each indication are clearly stated.
- All relevant comparator medicines presently included in the EML have been listed for each indication.
- The applicant presents sufficient evidence to support the proposed amendment.
- A supporting letter from the relevant MoPH department or program is included.

The same format is used for proposing deletions from the list. Often the proposal for inclusion of one medicine will also indicate the medicine to be replaced with that medicine. The medicine to be replaced will be deleted. If an existing medicine should be deleted without replacement, the same format can be used, indicating the medicine to be deleted in section 4 without, however, proposing a new medicine for replacement in section 3, but mentioning “to be removed” in section 3.

Types of Applications

Applications may address major or minor amendments.

Minor amendments include, but are not limited to, the following:

- New strengths, presentations, or administration forms of medicines already included in the EML (e.g., proposing the inhalator form of a bronchodilator that is already included as tablet, or injection or proposing slow-release instead of common tablets).
- Combination therapies using medicines already included in the EML

For minor amendments, the required supporting evidence should be relevant to the nature of the amendment (e.g., alignment with new WHO recommendations on strengths or combination therapies requires only a copy of the new WHO recommendations) and should include cost implications.

Major amendments include, but are not limited to, the following:

- New indications for existing items on the list (e.g., using a medicine included for its antihypertension properties as a tocolytic)
- New therapeutic entities (e.g., a new antibiotic such as doxycycline to replace a previously

included one such as tetracycline for the same indication)

- New therapeutic classes (e.g., antiretroviral medicines)

All major amendments must be supported by evidence reflecting safety, efficacy, and cost of the medicine compared to an already-listed medicine for the same indication. For inclusion of medicines already accepted in the LML list, reference to new MoPH guidelines, in line with WHO recommended practices may be sufficient. If the medicine is not on the LML list, please refer to the instructions in annex A of the LML.

Submittal and Screening Process

Applications are submitted to the GDPA of the MoPH. Upon receipt, the GDPA will acknowledge the receipt of the application in writing.

Applications are screened by the medicine technical selection committee (TSC) at the GDPA/MoPH to ensure that the following conditions have been met:

- The applicant's contact details are included.
- The medicine can be identified by its INN (i.e., generic name).
- At least one indication has been included along with the proposed regimen and cost.
- Relevant comparator medicine(s) have been identified with their corresponding dosing regimen(s).
- The cited evidence to substantiate the application is valid.
- A supporting letter from the relevant MoPH department or program is included.

The TSC will compile a review of the prevailing cost of therapy and assign the application to a suitably qualified reviewer who will prepare a technical report. This technical report summarizes a review of the submitted data and supporting references in terms of the following:

- Relative safety—Are the side effects acceptable considering the benefits for the patient who has the indicated condition?
- Relative efficacy—How do treatment results compare with treatment results of existing medicines for the stated condition?
- Practice environment—How does the proposed medicine's efficacy compare to current EML medicines?
- Pharmacoeconomic evaluation—How does the full treatment cost of the proposed medicine compare with the full treatment cost of existing medicines?

The report is then presented to the TSC, which may request further information from the applicant before recommending a decision to the NMSC.

The TSC will make one of the following recommendations to the NMSC for approval or rejection.

- If the NMSC decides that further review is required, the decision will be sent back to the TSC for further review.
- If the NMSC decides that the medicine is acceptable, the recommendation for approval will be submitted to the GDPA.
- If the NMSC decides that the medicine is not acceptable, the applicant will be informed of the rejection and of the reasons for rejection. A rejected medicine will not be reconsidered for inclusion within six months of the rejection. Resubmission requires significant additional information and supporting references that address the specific reason(s) for rejection of the original application.

Detailed Description of the Application Form

The application submission form contains five sections. Instructions for filling out the sections are provided here.

Section 1. Proposed Medicine Identification

- **Proposed Medicine:** Provide the proposed medicine’s INN, which identifies a pharmaceutical substance or active pharmaceutical ingredient by a unique name that is globally recognized and is public property. An INN is also known as a generic name. It also includes the presentation form and the strength of the proposed medicine (e.g., acetylsalicylic acid, tablet, 325 mg).
- **EML:** Indicate whether the proposed medicine should be included in the BPHS indicating the specific level(s), in the EPHS also indicating the specific level(s), or in both. If the medicine is intended for use by a special program or specialist physician, indicate the program or specialist in the special case.
- **Submission Date:** Give the Shamsi calendar date on which the submission is filled out.

Section 2. Applicant’s Details

The NMSC will acknowledge all submissions and communicate decisions with supporting arguments if appropriate. This section, therefore, forms a vital link between the applicant and the decision-making process.

- **Title:** give the full name of applicant with title
- **Name:** Give the full name of the applicant. Do not abbreviate (e.g., Mohammad, not Mhd.; Sayed, not S.).
- **Title/Department:** Provide the name of the department or entity for whom the applicant works.
- **Father’s Name:** Give the full name of the applicant’s father. Do not abbreviate (e.g., Mohammad, but Mhd.; Sayed, not S.).
- **Phone No.:** Give the phone number(s) at which the applicant can be contacted.
- **Postal Address:** Provide the full address where correspondence regarding the application should be sent. Include house number, street name, village or city, nahia, district, and province.
- **E-mail Address:** Give the e-mail address to which correspondence regarding the application can be sent.
- **Facility ID:** If applicable, provide the official MoPH facility code of the facility where the applicant works. If the applicant is a private practitioner working in a nonregistered facility, put “NA” for this entry.

Section 3. Proposed Indications

For each medicine submitted for inclusion, at least one indication with proposed regimen needs to be filled out. Up to three indications can be filled out for one medicine submitted for inclusion.

- **Indication:** The applicant may list up to three indications (conditions) for using the suggested medicine. The following are points to consider:
 - If the applicant suggests a new therapeutic class (i.e., a new or emerging disease or condition), a brief evidence based on Afghan epidemiological data, as well as inclusion status in the BPHS, the EPHS, or an MoPH special program, must be included as an annex.
 - The indication should allow for the identification of the appropriate comparator(s) in the current EML.
 - Many medicines have multiple indications. Not all indications are equally cost effective, however.

- **Proposed Regimen**

- *Dose*: The amount of the medicine to be given with each intake or administration
- *Route*: For example, oral, parenteral, or topical
- *Interval*: Expressed as one administration every so many hours
- *Duration*: Number of days for a full treatment; for chronic conditions, write “30”

These data will be used for cost comparison and are vital for the pharmacoeconomic evaluation of the application.

- **Cost Assessment**: Costs are expressed in either US dollars or Afghanis. Only one currency should be used. Using US dollars may facilitate comparisons with medicines available on the international market. The cost assessment of the proposed medicine is filled out by the applicant and will be double checked by the TSC.

- *Cost/Unit*: List the cost for one unit of the medicine. Clearly indicate the unit for which the cost is given.
- *Cost/Course*: List the cost for a complete treatment, or for one month’s treatment for medicines used in chronic conditions.

These data are necessary to determine affordability. The EML includes all medicines that are recommended for use in the public sector and eligible for subsidy to decrease costs for the patient and increase access to the medicines for the poor. For this reason, pharmacoeconomic data are considered mandatory for the decision to include a medicine in the EML.

- **Level of Evidence**: Cite, for each indication, the reference of the evidence that supports the use of the proposed medicine for that indication. Often this evidence will be the relevant WHO document or a document from another internationally accepted reference.

Section 4. Medicines on the Current EML with the Same Indication

As a principle, the addition of an EML item should replace an existing item. This principle is of particular importance when safety and economic implications are taken into account. For each indication, the applicant will give at least one comparator medicine. For new therapeutic classes, a comparator medicine is not required. Details of the comparator medicine include the following:

- **Medicine INN** (generic name). List the presentation form and strength.
- **Indication**. Cite (one of) the indication(s) listed in section 3.
- **Current Regimen**. List the regimen as was done for the proposed medicine.
- **Cost Assessment**. The cost assessment of the comparator medicines is done by the TSC.
- **Can Be Replaced by the Proposed Medicine**. The TSC’s conclusion of the comparison between current medicine and the proposed medicine (replace medicine, Yes or No).

Section 5. For Use by Pharmacy Department Only

This section is intended to ensure that the submissions follow the proper process. Dates of steps and decisions will be noted as appropriate. The section will allow the interested parties to quickly review the history of an application.


- **Application Number**: Upon receipt, the serial number of the application is noted. It consists of the number of the form, the four digits of the year of submission, and the serial number of submission in that year.
- **Correspondence**
 - *Date Received*: The date the application was received.
 - *Date Acknowledged*: The date a message was sent to the applicant confirming receipt.
 - *Application for More Evidence*: If applicable, the date a request for more evidence was

sent to the applicant. Only one request for more evidence will be sent per application for inclusion. Failure to submit convincing evidence will lead to rejection of the application for inclusion.

- Supporting Letter: The name of the MoPH department or program that supports the application for inclusion in the EML
 - Initial Evidence: The number or name of the reference given as initial evidence
 - Additional Evidence: The number or name of the reference given as additional evidence
 - Level of Evidence
 - Number of articles submitted initially
 - Number of articles submitted as additional evidence
- **Advice of TSC:** Whether the application is accepted or rejected
 - **Reason for Application:** Summarizes the reason(s) for the application. More than one option may be circled.
 - *New Medicine:* Application for a new medicine that is not yet on the EML
 - *New Strength or Presentation Form:* Application for a new strength or presentation form of a medicine already included in the EML
 - *New or Changed Condition:* Application to extend the use of an existing medicine to a condition for which it was previously not used or the condition it was previously accepted for has been changed (e.g., split into two or more new conditions)
 - *Change in Level of Care:* Application instigated by a change in STG or official MoPH protocols
 - *New Therapeutic Class:* Application for new medicines that address newly emergent conditions (e.g., HIV/AIDS medicines)
 - **Rejected by TSC:** The date the TSC rejected the application
 - **Forward to NMSC:** The date the TSC forwarded the application for final acceptance
 - **Accepted by NMSC:** The date the NMSC accepted the medicine for inclusion
 - **Rejected by NMSC:** The date the NMSC rejected the medicine for inclusion
 - **Signature and Stamp of API:** API director's signature and stamp
 - **Signatures and Stamp of GDPA:** GDPA director's signature and stamp

The applicant will be informed in writing of the final decision. Figure A1 summarizes the application process.

Figure A1. Flow of application for inclusion in the EML



Notes on the Application Process

Evidence

Evidence is a vital component of the submission and review process. Evidence does not constitute a medicine decision and merely informs the strength of the argument. It forms the basis upon which the decision is made and allows for transparent scrutiny of the decision as well as facilitating the review. Evidence is required in support of the following:

- Relative efficacy
- Relative safety
- Relative cost
- Pharmacoeconomic benefits

Evidence needs to be relevant to the Afghan context. Multinational or foreign studies must be relevant to both the outcome measures as well as socioeconomic issues for the Afghan context. The inclusion of at least one relevant reference is mandatory.

For application of an existing medicine to a new indication or for the introduction of a new medicine or new class of medicines, a copy of the full journal article should be included to expedite the review process.

Communication of the Decision

After processing, the decision regarding an application will be communicated in writing to the applicant. In case of rejection of the application, the exact reasons for rejection will be provided.

Reconsidering a Rejected Application

As a rule, a rejected application will not be reconsidered within six months after the rejection. To qualify for reconsideration, compelling additional evidence as described above should accompany the resubmission.

فرم درخواست افزودن/کاستن ادویه های ملی ادویه مجاز
Application Form for Medicine Including or Excluding a Medicine in the EML

Section 1. Proposed Medicine Identification		بخش اول: معرفی دوا پیشنهادی	
INN یا نام جنریک			
Form یا شکل دوايي	Father's Name ولد		
Strength یا قدرت	Title/Dept. وظيفه و محل آن		
LML افزودن/کاستن در	Phone No. شماره تلفون		
Special	Dispensary	CSL یا ادويه تحت کنترل	Postal Address آدرس پستی
		OTC	E-mail Address ایمیل آدرس
Submission Date تاريخ ارائه درخواست	Health Facility ID کد نمبر مرکز صحتی		

Section 2. Applicant's Details		بخش دوم: تفصیلات درخواست کننده:	
Name اسم			
Father's Name ولد			
Title/Dept. وظيفه و محل آن			
Phone No. شماره تلفون			
Postal Address آدرس پستی			
E-mail Address ایمیل آدرس			
Health Facility ID کد نمبر مرکز صحتی			

Section 3. Proposed Indications						بخش سوم: مشخصات دواي پیشنهاد شده	
Level of Evidence سطح شواهد	Proposed Regimen رژیم دواي پیشنهادی			Cost Assessment ارزشیابی قیمت		Cost/Course قیمت کورس مکمل دواي	
	Dose مقدار	Route طرق تطبیق	Interval مدت وقفه	Duration دوره دواي	Cost/Unit قیمت فی واحد		
استطبیب							

- | | |
|--|--|
| <p>Level of Evidence سطح شواهد</p> <ul style="list-style-type: none"> Ia. Meta-analysis فرا تحلیل Ib. Randomized controlled trial کار آزمائی کنترل شده تصادفی II. Controlled study with no randomization مطالعه کنترل غیر تصادفی III. Comparative, correlation or case control study (مطالعه کنترل واقعه وی - مقایسوی و مشاهده وی) IV. Reliable textbooks کتب معتبر V. Any other valid references منابع معتبر دیگر | <p>(تجارب کلینیکی Clinical experience, کمیته متخصصین Expert committee)</p> |
|--|--|

Section 4. Medicines on current EML or LML with the same indication

بخش چهارم : دوائی موجوده در لیست ادویه اساسی یا مجاز با عین موارد استعمال	Current Regimen				Cost Assessment		Can be replaced by proposed medicine می‌تواند با دوائی پیشنهادی تعویض گردد
	Indication استنباب	Dose مقدار	Route طرق تطبیق	Interval مدت وقفه	Duration دوره تداوی	Cost/Unit قیمت فی واحد	
Medicine دوا					Days روزها		
					Days روزها		
					Days روزها		
					Days روزها		

Section 5. For Use by General Directorate of Pharmaceutical Affairs Only

بخش پنجم : این بخش توسط دبیرتتمت مربوط در اداره امور فارمسی تکمیل میشود

Application Number
شماره درخواستی

Correspondence مراسله	Date Received تاریخ دریافت	Acknowledged تصدیق شد	Application for more evidence مطالبه شواهد بیشتر
	/ /	/ /	/ /

Supporting letter from: Initial evidence Additional evidence

Evidence	Number of articles submitted initial تعداد مقاله های ارایه شده ابتدایی	Number of articles submitted as additional evidence شواهد اضافی
	/ /	/ /

Advice of TSC: Accept/Reject	Reason for application:	Number of articles submitted as additional evidence
	<input type="checkbox"/> New medicine <input type="checkbox"/> Change in level of care <input type="checkbox"/> New strength or presentation form <input type="checkbox"/> New or changed condition	

Rejected by TSC: کمیته تکنیکی فارمسی مسترد نمود	Forward to NMSC: ارجاع به کمیته ملی انتخاب ادویه	Accepted by NMSC: تصویب کمیته ملی انتخاب ادویه	Rejected by NMSC: توسط کمیته ملی انتخاب ادویه رد شد
/ /	/ /	/ /	/ /

API Director Signature: امضاء رئیس انستیتوت فارمسی این سینا	API Stamp مهر ریاست انستیتوت فارمسی این سینا	GDPA Director Signature: امضای رئیس امور فارمسی
--	---	--

References

- British Medical Association. 2009. *National British Formulary*, Volume 57. London: BMJ Group and RPS Publishing.
- International Narcotics Control Board. 2004. *List of Narcotic Drugs under International Control, Yellow List* (46th ed.) Vienna, Austria: International Narcotics Control Board.
- Islamic Republic of Afghanistan. *National Malaria Strategic Plan 2006–2010*. Kabul: MoPH.
- Islamic Republic of Afghanistan. 2006. *National Policy on Reproductive Health*. Kabul: MoPH.
- Islamic Republic of Afghanistan. 2007. *Licensed Drugs List of Afghanistan*. Kabul: Drugs and Therapeutics Committee, Essential Drugs Department, Ministry of Health, and MoPH.
- Islamic Republic of Afghanistan. 2008. *Malaria Treatment Protocol 2008*. Kabul: MoPH.
- Islamic Republic of Afghanistan. 2010. *A Basic Package of Health Services for Afghanistan*. Kabul: MoPH.
- Islamic Republic of Afghanistan. 2013. *The Essential Package of Hospital Services for Afghanistan*. Kabul: MoPH.
- Martindale, William, and James E.F. Reynolds (eds.) 1996. *Martindale the Extra Pharmacopoeia* (31st ed.) London: Royal Pharmaceutical Society.
- MSH. 2006. *International Drug Price Indicator Guide*. 2006. Arlington, Virginia, USA: Center for Pharmaceutical Management, MSH.
- MSH and WHO. 1997. *Managing Drug Supply*. West Hartford, Connecticut, USA: Kumarian Press.
- Transitional Islamic Government of Afghanistan. 2003. *HIV/AIDS and STI National Strategic Plan for Afghanistan 2003-2007*. Kabul: MoPH.
- Transitional Islamic Government of Afghanistan. 2003. *IMCI Chart Booklet*. Kabul: Ministry of Health.
- Transitional Islamic Government of Afghanistan. 2003. *National Medicine Policy*. Kabul: Ministry of Health.
- Transitional Islamic Government of Afghanistan. 2007. *National Essential Drugs List of Afghanistan*. Kabul: Drugs and Therapeutics Committee, Essential Drugs Department, Ministry of Health.
- WHO. 2008. *WHO Model Formulary*. Geneva: WHO.
- WHO. 2013. *WHO Model List of Essential Medicines*. Geneva: WHO.
<http://www.who.int/medicines/publications/EML15.pdf> and
http://www.who.int/medicines/services/essmedicines_def/en/index.html
- WHO, International Planned Parenthood Federation, and John Snow Inc. 2006. *The Interagency List of Essential Medicines for Reproductive Health*. Geneva: WHO.
- WHO Collaborating Center for Drug Statistics Methodology and Norwegian Institute of Public Health. 2012. *ATC Index with DDDs*, 2013. Oslo: Norwegian Institute of Public Health.
<http://www.whocc.no/atcddd/>

Medicines Index

- Abacavir, 29, 44, 60
Acetazolamide, 41, 44
Acetylcysteine, 42, 44
Acetylsalicylic acid, 16, 34, 35, 44
Aciclovir, 41, 44
Adrenalin, 34, 44
Albendazole, 39, 44
Allopurinol, 33, 44
Alprazolam, 36, 44
Aluminium hydroxide, 13, 44
Amikacin, 27, 44, 63
Aminophylline, 40, 44
Amitriptyline, 37, 44
Amlodipine, 19, 44
Amoxicillin, 11, 25, 44
Ampicillin, 9, 25, 44
Artemether, 38, 45, 62
Artesunate, 38, 45, 62
Atazanavir, 29, 45, 60
Atenolol, 19, 45
Atorvastatin, 20, 45
Atropine sulfate, 13, 41, 42, 45
Azithromycin, 26, 45
- Bacitracin, 11, 21, 45
Barium sulfate, 43, 45
Beclometasone dipropionate, 40, 45
Benzoic acid, 39, 45
Benzoyl peroxide, 22, 45
Benzyl benzoate, 39, 45
Betamethasone, 22, 45
Biperiden, 36, 45
Bisacodyl, 14, 45
Boric acid, 22, 42, 45
Bromocriptine mesylate, 36, 45
Bupivacaine, 34, 45
Buprenorphine, 37, 45, 61
- Calamine, 21, 46
Calcium gluconate, 15, 46
Capreomycin, 28, 46, 63
Captopril, 20, 46
Carbamazepine, 35, 46
Carbidopa, 36, 46
Carbimazole, 24, 46
Ceftriaxone, 26, 46
Cetrimide, 22, 46
Charcoal, activated, 14, 44
Chloramphenicol, 25, 41, 46
Chlordiazepoxide, 36, 46
Chlorhexidine digluconate, 22, 46
Chloroquine, 38, 46, 62
Chlorphenamine maleate, 40, 46
Chlorpromazine, 36, 46
Ciclosporin, 33, 46
Ciprofloxacin, 27, 46
Clindamycin, 26, 46
Clofazimine, 29, 46, 64
- Clomifene, 24, 46
Clomipramine, 37, 46
Cloxacillin, 25, 46
Coal tar, 21, 47
Colchicine, 33, 47
Colecalciferol, 15, 46, 66
Colestyramine, 20, 47
Cycloserine, 28, 47, 63
- Dapsone, 29, 47, 64
Deferoxamine mesylate, 42, 47
Delavirdine, 29, 47
Dextran, 17, 47
Diatrizoic acid, 43, 47
Diazepam, 36, 37, 47
Diclofenac, 33, 47
Digoxin, 18, 47
Dimenhydrinate, 40, 47
Dimercaprol, 42, 47
Diphenhydramine chloride, 40, 47
Diphenhydramine teoclate, 40, 47
Diphtheria, 31, 32, 47, 65
Diphtheria antitoxin, 31, 47
Dopamine, 18, 47
Doxycycline, 24, 47
- Efavirenz, 29, 47, 48, 60
Emtricitabine, 29, 48, 60
Enalapril, 20, 48
Enfuvirtide, 30, 48, 60
Enoxaparin, 16, 48
Entecavir, 30, 48, 60
Epinephrine, 18, 48
Ergometrine maleate, 23, 48
Ergotamine, 35, 48
Erythromycin, 26, 27, 48
Ethambutol, 28, 48, 63
Ethinylestradiol, 23, 24, 32, 48, 59
Ethionamide, 28, 48, 63
Ethosuximide, 35, 48
Etravirine, 30, 48, 60
- Fenofibrate, 20, 49
Ferrous sulfate, 16, 49
Flumazenil, 42, 49
Fluorouracil, 32, 49
Fluoxetine, 37, 49
Fluphenazine, 36, 49
Folic acid, 15, 17, 49
Fosamprenavir, 30, 49
Furazolidone, 22, 49
Furosemide, 19, 49
- Gentamicin, 27, 41, 49
Glibenclamide, 14, 49
Glucose, 12, 14, 17, 34, 49
Glycerin, 22, 42, 45
Glyceryl trinitrate, 18, 49
Griseofulvin, 21, 49
- Haloperidol, 36, 49
Halothane, 33, 49
Heparin, 16, 49, 50
Hydralazine, 19, 50
Hydrochlorothiazide, 19, 50
Hydrocortisone acetate, 22, 50
Hydrocortisone sodium succinate, 24, 50
Hydrogen peroxide, 22, 50
Hydroxocobalamin, 17, 50
Hyoscine, 13, 50
Ibuprofen, 33, 50
- Imipramine, 37, 50
Immunoglobulin, antitetanus, 31, 44
Indinavir, 30, 50, 60
Insulin isophane, 14, 50
Insulin soluble fast, 14, 50
Iodine, 24, 50, 67
Iron dextran, 16, 50
Isoflurane, 33, 50
Isoniazid, 28, 50, 63
Isosorbide dinitrate, 18, 50
- Ketamine, 33, 51
Ketoconazole, 20, 27, 51
- Lactulose, 14, 51
Lamivudine, 30, 51, 60
Levonorgestrel, 23, 51, 59
Levothyroxine, 24, 51
Lidocaine, 18, 21, 34, 51
Lindane, 39, 51
Lopinavir, 30, 51, 60
- Magnesium sulfate, 35, 51
Mannitol, 17, 51
Maraviroc, 30, 51, 60
Measles diluent, 32, 51
Measles vaccine, 32, 51, 65
Mebendazole, 39, 51
Medroxyprogesterone acetate, 23, 51, 59
Meglumine antimoniate, 39, 52, 62
Metformin, 14, 52
Methadone, 37, 52, 61
Methotrexate, 33, 52
Methyldopa, 18, 52
Methylene blue, 42, 52
Methylergometrine maleate, 23, 52
Methylrosaniline, 20, 52
Metoclopramide, 13, 52
Metoprolol, 19, 52
Metronidazole, 21, 27, 38, 52
Midazolam, 37, 52
Misoprostol, 23, 52, 59
Morphine, 34, 52

Moxifloxacin, 27, 52, 63
 Multivitamins, 11, 15, 52
 Mupirocin, 21, 52

 Nalidixic acid, 27, 52
 Naloxone, 42, 52
 Naphazoline, 39, 52
 Nelfinavir, 30, 52, 53, 60
 Neomycin sulfate, 41, 53
 Neostigmine bromide, 37, 53
 Neostigmine methylsulfate, 37, 53
 Niclosamide, 39, 53
 Nifedipine, 20, 23, 53
 Nitrofurantoin, 27, 53
 Norethisterone, 24, 53
 Norgestrel, 23, 53, 59
 Nortriptyline, 37, 53
 Nystatin, 14, 20, 22, 53

 Omeprazole, 13, 53
 Opium tincture, 37, 53, 61
 Oral rehydration salts, 12, 14, 53
 Oxygen, 42, 53
 Oxytocin, 24, 53

 Para-aminosalicylic acid, 28, 53, 63
 Paracetamol, 35, 53, 54
 Penicillamine, 33, 54
 Penicillin benzyl, 25, 26, 54
 Penicillin benzyl benzathine, 26, 54
 Penicillin benzyl procaine, 26, 54
 Penicillin V, 26, 54
 Permethrin, 39, 54
 Pethidine, 34, 54
 Phenobarbital, 35, 36, 54
 Phytomenadione, 16, 54, 67
 Pilocarpine, 41, 54
 Pneumococcal conjugated vaccine, 32, 54, 65
 polio vaccine, oral, 32, 53, 65
 Potassium chloride, 12, 18, 54
 Potassium iodide, 42, 54
 Potassium permanganate, 22, 54
 Povidone iodine, 22, 54
 Pralidoxime, 42, 54
 Prednisolone, 24, 41, 54
 Primaquine, 38, 54, 62
 Procainamide, 18, 55
 Promethazine, 40, 55
 Propofol, 33, 34, 55
 Propranolol, 19, 55
 Protamine sulfate, 42, 55
 Pyrazinamide, 28, 55, 63
 Pyridoxine, 15, 55

 Quinine dihydrochloride, 38, 55, 62
 Quinine sulfate, 39, 55, 62

 Rabies antitoxin, 31, 55

 Raltegravir, 31, 55, 60
 Ranitidine, 13, 55
 Retinol, 15, 21, 55, 66
 Rifampicin, 28, 29, 55, 56, 63, 64
 Ringer's lactate, 17, 56
 Ritonavir, 31, 56, 60
 Rotavirus monovalent, 32, 56, 65
 Rubella vaccine, 32, 56, 65

 Salbutamol, 39, 40, 56
 Salicylic acid, 20, 56
 Saquinavir, 31, 56, 60
 Scorpion antivenom, 31, 56
 Silver sulfadiazine, 21, 56
 Sodium bicarbonate, 18, 56
 Sodium chloride, 12, 17, 39, 56
 Sodium hypochlorite, 22, 56
 Sodium stibogluconate, 39, 56, 62
 Spironolactone, 19, 56
 Stavudine, 31, 56, 60
 Streptomycin, 27, 29, 56, 63
 Sulfacetamide, 41, 56
 Sulfamethoxazole, 26, 56
 Sulfasalazine, 33, 56
 Sulfur, 22, 56
 Suxamethonium, 33, 56

 Tenofovir, 60
 Terbinafine, 20, 21, 57
 Tetanus toxoid vaccine, 32, 57, 65
 Tetracaine, 41, 57
 Tetracycline, 41, 57
 Thiopental sodium, 34, 57
 Timolol, 41, 57
 Tramadol, 34, 57
 Trihexyphenidyl, 36, 57
 Tropicamide, 41, 57
 Tuberculin purified protein derivative, 42, 57
 Tuberculosis vaccine, 32, 57, 65

 Valproic acid, 36, 57
 Vaseline, 43, 57
 Verapamil, 20, 57

 Zidovudine, 31, 57, 58, 60, 61
 Zinc oxide, 21, 58
 Zinc sulfate, 16, 58

This list is made possible by the generous support of the American people through the US Agency for International Development (USAID), under the terms of cooperative agreement number GHN-A-00-07-00002-00. The contents are the responsibility of Ministry of Public Health of the Islamic Republic of Afghanistan with technical support of Management Sciences for Health and the World Health Organization, Eastern Mediterranean Regional Office and do not necessarily reflect the views of USAID or the United States Government.

About SPS:

The Strengthening Pharmaceutical Systems (SPS) Program strives to build capacity within developing countries to effectively manage all aspects of pharmaceutical systems and services. SPS focuses on improving governance in the pharmaceutical sector, strengthening pharmaceutical management systems and financing mechanisms, containing antimicrobial resistance, and enhancing access to the most efficacious, safe and cost-effective medicines and appropriate use of medicines.



